Comorbidities increase the risk of severity and mortality in COVID-19 patients: a

systematic review and meta-analysis

Comorbidades aumentam o risco de gravidade e mortalidade em pacientes com COVID-19: uma revisão sistemática e metanálise

Comorbilidades aumentan el riesgo de gravedad y mortalidad en pacientes con COVID-19: una

revisión sistemática y metanálisis

Received: 02/01/2021 | Reviewed: 02/12/2021 | Accept: 02/18/2021 | Published: 02/25/2021

Edilson Leite de Moura ORCID: https://orcid.org/0000-0001-6216-6522 Universidade Federal de Alagoas, Brasil E-mail: edilsonleite17@hotmail.com Jean Moises Ferreira ORCID: https://orcid.org/0000-0002-6554-0337 Universidade Federal de Pernambuco, Brasil E-mail: jean.moises@hotmail.com Ana Caroline Melo dos Santos ORCID: https://orcid.org/0000-0003-0280-6107 Universidade Federal de Alagoas, Brasil E-mail: anacaroline12305@gmail.com Denise Macedo da Silva ORCID: https://orcid.org/0000-0002-2294-6660 Universidade Federal de Alagoas, Brasil E-mail: denise.macedo15@hotmail.com Maria Lidiane Ferreira da Silva ORCID: https://orcid.org/0000-0002-4679-1069 Universidade Federal de Alagoas, Brasil E-mail: lidianebiologia2018@gmail.com Gleyce Kelly Marques de Oliveira Silva ORCID: https://orcid.org/0000-0003-1650-1718 Universidade Federal de Alagoas, Brasil E-mail: gleycekelly1844@gmail.com Pedro Henrique Nobre Silva ORCID: https://orcid.org/0000-0003-1994-6480 Universidade Federal de Alagoas, Brasil E-mail: pehnobre@gmail.com José Anderson dos Santos ORCID: https://orcid.org/0000-0002-4182-4693 Universidade Federal de Alagoas, Brasil E-mail: jose.anderson.s.2013@gmail.com Marcos Antônio da Silva Barbosa Junior ORCID: https://orcid.org/0000-0002-7759-4981 Universidade Federal de Alagoas, Brasil E-mail: marcosantoniojunior.s15@gmail.com Abel Barbosa Lira Neto ORCID: https://orcid.org/0000-0001-7597-3761 Universidade Federal de Alagoas, Brasil. E-mail: abel.neto@arapiraca.ufal.br Aline Cristine Pereira e Silva ORCID: https://orcid.org/0000-0002-9620-5654 Universidade Federal de Alagoas, Brasil E-mail: aline_ufal@yahoo.com.br Carlos Alberto de Carvalho Fraga ORCID: https://orcid.org/0000-0002-9564-9595 Universidade Federal de Alagoas, Brasil E-mail: carlos.fraga@arapiraca.ufal.br Karol Fireman de Farias ORCID: https://orcid.org/0000-0003-1352-2513 Universidade Federal de Alagoas, Brasil E-mail: karolfireman@hotmail.com

Elaine Virginia Martins de Souza Figueiredo ORCID: https://orcid.org/0000-0001-9724-5861 Universidade Federal de Alagoas, Brasil E-mail: elainevms@yahoo.com.br

Abstract

Introduction: Several studies have shown that patients with comorbidities present a poor clinical outcome of COVID-19, but the conclusions are not yet consolidated. We conducted a meta-analysis to evaluate the relationship between the preexistent conditions (comorbidities) in patients infected with SARS-CoV-2 and the outcome of COVID-19. Methods: PubMed, Science Direct, ISI Web of Science and Scopus databases were examined up to November 2020. We calculated the pooled odds ratio (OR) with 95% confidence interval, using fixed-effects or random-effects models. Results: A total of 48 retrospective cohort studies with 344,290 COVID-19 patients were included in the metaanalysis. The pooled results showed that hypertension, diabetes, cardiovascular, chronic pulmonary, chronic kidney and cerebrovascular diseases increase the risk of severity and mortality in COVID-19 patients. Moreover, malignancy was associated with an increased risk of death from COVID-19. Conclusions: The comorbidities previously mentioned may be important predictors of poor outcome of COVID-19, contributing to the prognosis of severe cases of the disease. (TNR font 10 – simple space)

Keywords: Coronavirus; Comorbidities; Chronic disease; COVID-19 and SARS-CoV-2.

Resumo

Introdução: Vários estudos têm mostrado que pacientes com comorbidades apresentam um pobre desfecho clínica da COVID-19, mas as conclusões ainda não estão consolidadas. Nós conduzimos uma metanálise para avaliar a relação entre as condições preexistentes (comorbidades) em pacientes infectados com SARS-CoV-2 e o desfecho da COVID-19. Métodos: Os bancos de dados PubMed, Science Direct, ISI Web of Science e Scopus foram examinados até novembro de 2020. Nós calculamos o odds ratio (OR) com intervalo de confiança de 95%, usando modelos de efeitos fixos ou aleatórios. Resultados: Um total de 48 estudos de coorte retrospectivos com 344.290 pacientes com COVID-19 foram incluídos na metanálise. Os resultados combinados mostraram que hipertensão, diabetes, doenças cardiovasculares, pulmonares crônicas, renais crônicas e cerebrovasculares aumentam o risco de gravidade e mortalidade em pacientes com COVID-19. Além disso, a malignidade foi associada a um risco aumentado de morte por COVID-19. Conclusões: As comorbidades citadas anteriormente podem ser importantes preditores de pobre desfecho da COVID-19, contribuindo para o prognóstico de casos graves da doença.

Palavras-chave: Coronavírus; Comorbidades; Doenças crônicas; COVID-19 e SARS-CoV-2.

Resumen

Introducción: Varios estudios han demostrado que los pacientes con comorbilidades presenten un mal pronóstico clínico de COVID-19, pero las conclusiones aún no están consolidadas. Realizamos un metanálisis para evaluar la relación entre las condiciones preexistentes (comorbilidades) en pacientes infectados con SARS-CoV-2 y el resultado de COVID-19. Métodos: Se examinaron las bases de datos PubMed, Science Direct, ISI Web of Science y Scopus hasta noviembre de 2020. Nosotros calculamos el odds ratio (OR) con un intervalo de confianza del 95%, utilizando modelos de efectos fijos o de efectos aleatorios. Resultados: Se incluyeron en el metanálisis un total de 48 estudios de cohorte retrospectivos con 344,290 pacientes con COVID-19. Los resultados combinados mostraron que la hipertensión, la diabetes, las enfermedades cardiovasculares, pulmonares crónicas, renales crónicas y cerebrovasculares aumentan el riesgo de gravedad y mortalidad en los pacientes con COVID-19. Además, la malignidad se asoció con un mayor riesgo de muerte por COVID-19. Conclusiones: Las comorbilidades mencionadas anteriormente pueden ser importantes predictores de mala evolución del COVID-19, contribuyendo al pronóstico de los casos graves de la enfermedade.

Palabras clave: Coronavirus; Comorbilidades; Enfermedades crónicas; COVID-19 e SARS-CoV-2.

1. Introduction

In December 2019, an outbreak that started in Wuhan - China, gave rise to Coronavirus disease 2019 (COVID-19) (Lin et al., 2020a; Tian et al., 2020a). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 shows a high transmission capacity and infected patients may be asymptomatic or develop a moderate (non-severe) to severe form of the disease (Lai et al., 2020; Tay et al., 2020).

The clinical conditions of patients may change rapidly, leading to severe pneumonia and, eventually, to acute respiratory distress syndrome, septic shock and/or multiple organ failure, which lead to a considerable number of deaths (Alhazzani et al., 2020; Moccia et al., 2020; Moore et al., 2020). COVID-19 mortality is a serious global problem today.

Several researches are focused on the development of vaccines and medicines, and recent discoveries may make treatment and prophylaxis a reality for the very near future (Abd El-Aziz & Stockand, 2020; Robson, 2020). Thus, understanding the dynamics of the virus, as well as the tendency of patients to develop a poor prognosis, is vital, and this information may provide better patient care and effectively reduce the mortality of the disease (Azkur et al., 2020; Zheng et al., 2020b).

Analysis of COVID-19 patients showed that susceptibility to severe SARS-CoV-2 infection varies between different groups of patients (Lee et al., 2020; Shi et al., 2020b). Some studies have shown that pre-existing conditions before symptomatic SARS-CoV-2 infection increase the severity of the disease, leading to poor patient prognosis (Li et al., 2020d; Yang et al., 2020a). Hypertension, chronic obstructive pulmonary disease (COPD), malignancy, diabetes, cardiovascular, renal, liver and cerebrovascular diseases have been described as possible factors of severity in patients with COVID-19 and in cases of fatality (Yang et al., 2020a; Yang et al., 2020c).

The literature on SARS-CoV-2 and COVID-19 has grown and changed rapidly in response to the need for new data on the virus (Harwood & Sinha, 2020; Lin et al., 2020b; Rando et al., 2020). For this reason, we performed a meta-analysis to affirm the relationship between pre-existing conditions (comorbidities) in patients infected with SARS-CoV-2 and the outcome of COVID-19. (TNR font 10 – justified – space 1,5).

2. Methodology

2.1 Search Strategy

To assess the association of pre-existing comorbidities with the severity and mortality of COVID-19, we performed a systematic review with a quantitative approach (meta-analysis), in which analyze the pooled data of the articles included (de Moura et al., 2020; Pereira et al., 2018). The review followed recommendations from Preferred Reporting Items for Systematic Reviews and Meta-analysis (Prisma) (Moher et al., 2009). The following databases were examined until November 2020: PubMed, Science Direct, ISI Web of Science and Scopus. The search keywords with the combinations used were "coronavirus", "COVID-19", "SARS-CoV-2" and "clinical characteristics"; using Boolean connectors "And", "Or" and "And Not". Descriptors were defined using the PICOS method (Santos et al., 2007). Participants (P): COVID-19 patients who have the severe form of the disease or who have died; the intervention (I): identification of comorbidities; control groups (C): COVID-19 patients without the severe form of the disease or who have recovered from the disease; outcome (O): presence or absence of comorbidities in the group of patients with non-severe or severe COVID-19 and patients who recovered or have died from COVID-19; Study design (S): a retrospective cohort. The surveys were not limited by the language or country of the primary studies. However, only articles published in English were qualified.

2.2. Eligibility criteria

The inclusion criteria to select studies in our meta-analysis were: (1) studies with a retrospective cohort design; (2) studies that assessed the association between comorbidities and severe COVID-19; (3) studies that assessed the association between comorbidities and death in COVID-19 patients. The exclusion criteria were: (1) systematic/integrative/narrative review; (2) letters to editors; (3) case reports; (4) editorials, (5) conference abstracts, and (6) duplicates articles.

2.3. Evaluation of studies

Titles, abstracts and full articles were independently assessed by three researchers (ELM, DMS and ACMS). Inconsistencies among the researchers were elucidated by discussion after re-evaluating the article. Three investigators separately assessed the quality of the included studies using the Newcastle–Ottawa Scale (NOS) standards (PHNS, JAS, and MASBJ) (Stang, 2010). The quality of the studies was classified as low quality (score < 4), medium quality (score 4-6) and high quality (score > 7). The authors' evaluation form is summarized in Supplementary 1.

2.4. Data extraction

The data of interest for each accepted study were extracted into a data extraction form developed specifically for this systematic review. We extracted the following variables: author, year of publication, sex, average age, number of participants, number of patients with comorbidities. Subsequently, they were categorized as patients with severe and non-severe COVID-19; patients who died and recovered from COVID-19. Two investigators collected information from each study, and a third investigator independently reviewed the extracted data for completeness and accuracy from the original studies (MLFS, GKMOS, JMF).

2.5. Statistical analysis

Review Manager (version 5.3) software was used for statistical analysis, considering Odds Ratio (OR) and an estimate of the 95% confidence intervals (CIs) for each study and the pooled OR were established by Z test (p < .05). The results were calculated to assess the sensitivity. The I2 statistic and Cochran's Q test (Higgins & Thompson, 2002) were used to assess statistical heterogeneity. We calculated the pooled ORs using fixed-effects model (when P heterogeneity > 0.05 or I2 < 50%) and random-effects model (when P heterogeneity < 0.05 or I2 > 50%). Egger's test was calculated to detect bias in comparisons, using the metafor package (Nicodemus, 2008) in the R Project for Statistical version 3.6.2. (TNR font 10 - justified – space 1,5).

3. Results

3.1 Search results

Searches in the four databases identified a total of 3,228 articles (PubMed: 1283, Scopus: 947, Web of Science: 755, Science Direct: 243). After removing duplicates, 1,546 articles were considered for the studies selection process. From the 1,546 articles, 1,421 were excluded after analysis of titles and abstracts. Thus, 125 full-text articles were carefully reviewed. Applying the inclusion and exclusion criteria, 48 studies were included in the qualitative and quantitative (meta-analysis) synthesis (Figure 1).

The data for all participants included in the meta-analysis (344,290 COVID-19 patients) were divided into subgroups, according to patient characteristics. The first subgroup included studies that analysed non-severe and severe cases of COVID-19 (2,501 severe and 6,567 non-severe patients) (Charlotte et al., 2020; Chen et al., 2020a; Dang et al., 2020; de la Rica et al., 2020; Fang et al., 2020; Feng et al., 2020; Guan et al., 2020; He et al., 2020a; He et al., 2020b; Huang et al., 2020; Jiang et al., 2020; Jiang et al., 2020; Li et al., 2020a; Li et al., 2020b; Li et al., 2020c; Li et al., 2020; Li et al., 2020a; Shi et al., 2020a; Shi et al., 2020a; Wang et al., 2020a; Wang et al., 2020b; Lv et al., 2020; Shi et al., 2020a; Shu et al., 2020; Wang et al., 2020a; Wang et al., 2020b; Wang et al.,


The second subgroup was composed of studies that evaluated hospitalized COVID-19 patients who recovered or died (39,722 died and 295,500 recovered) (Chen et al., 2020b; Chen et al., 2020c; Chen et al., 2020d; Deng et al., 2020; Guisado-Vasco et al., 2020; Hu et al., 2020; Javanian et al., 2020; Li et al., 2020c; Morrison et al., 2020; Ñamendys-Silva et al., 2020; Parra-Bracamonte et al., 2020; Shang et al., 2020; Vena et al., 2020; Wu et al., 2020; Xie et al., 2020; Yao et al., 2020; Zhou et al., 2020). The characteristics of the studies included in the meta-analysis are shown in Tables 1A and 1B.


3.2 Meta-analysis

3.2.1 Hypertension

Thirty-four studies (2,501 severe and 6,567 non-severe COVID-19 patients) were included in the meta-analysis to assess susceptibility to severe COVID-19 in hypertensive individuals. The pooled ORs showed that patients with hypertension had a 2.38-fold increased risk of developing the severe form of COVID-19 (OR = 2.38 [95% CI = 1.91 - 2.96], P < 0.00001)

(Table 2). The forest plot of this association is shown in Figure 2A. In this analysis, the Egger test confirmed the presence of publication bias (Egger test: Z = 6.9149, P < 0.0001). Furthermore, heterogeneity was detected among the included studies ($\chi 2 = 86.94$, P < 0.00001, I2 = 62%) (Table 2).





From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Source: author of this research (2020).

Research, Society and Development, v. 10, n. 2, e50010212533, 2021 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v10i2.12533

Table 1A - Characteristics of the studies included in the meta	a-analyses.
--	-------------

Author	Patients		Patients			Country	Age	Groups				Comorbidit	ies			
	All	Female	Male	-	(median)		Hypertension	Diabetes	Cardiovascular disease	CPD	CKD	Cerebrovascular disease	CLD	Malignancy		
Charlotte et al., 2020	196	77	119	Switzerland	70	Without ICU stay vs. With ICU stay	118 (60.2%)	52 (26.5%)	47 (24.0%)	16 (8.2%)	0	0	0	15 (7.6%)		
Chen(1) et al., 2020	48	11	37	China	64.4	Severe/critically vs. Moderate	23 (49.7%)	12 (25%)	8 (16.7%)	2 (4.2%)	0	6 (12.5%)	4 (8.3%)	6 (12.5%)		
Chen(2) et al., 2020	203	95	108	China	54	Died vs. Survived	43 (21.2%)	16 (7.9%)	16 (7.9%)	8 (3.9%)	8 (3.9%)	9 (4.4%)	8 (3.9%)	7 (3.4%)		
Chen(3) et al., 2020c	274	103	171	China	62	Death vs. Recovered	93 (33.9%)	47 (17.1%)	23 (8.4%)	18 (6.6%)	4 (1.5%)	4 (1.5%)	0	7 (2.5%)		
Chen(4) et al., 2020	681	319	362	China	65	Survivors vs. Non-survivors	293 (43.0%)	114 (16.7%)	80 (11.7%)	15 (2.2%)	27 (4.0%)	33 (4.8%)	0	0		
Dang et al., 2020	17	5	12	China	88	Severe vs. Non-severe	9 (52.9%)	5 (29.4%)	8 (47.1%)	3 (17.6%)	6 (35.3%)	0	0	2 (11.8%)		
Deng et al., 2020	225	101	124	China	NP	Death vs. Recovered	58 (25.8%)	26 (11.6%)	17 (7.6%)	25 (11.1%)	0	0	0	8 (3.6%)		
Fang et al., 2020	1,280	665	615	China	NP	POTC vs. PSTC vs. PCTC	423 (33.0%)	184 (14.4%)	130 (10.2%)	36 (2.8%)	20 (1.6%)	13 (1.0%)	17 (1.3%)	13 (1.0%)		
Feng et al., 2020	476	205	271	China	53	Severe/critically vs. Moderate	113 (23.7%)	49 (10.3%)	38 (8%)	22 (4.6%)	4 (0.8%)	17 (3.6%)	0	12 (2.5%)		
Guan et al., 2020	1,099	459	640	China	47	Severe vs. Non-severe	165 (15%)	81 (7.4%)	27 (2.5%)	12 (1.1%)	8 (0.7%)	15 (1.4%)	23 (2.1%)	10 (0.9%)		
Guisado-Vasco et al., 2020	607	212	394	Spain	69	Survivors vs. Non-survivors	276 (46.9%)	95 (16.2%)	133 (22.6%)	114 (19.4%)	22 (3.7%)	21 (3.6%)	24 (4.1%)	77 (13.1%)		
He(1) et al., 2020	288	157	131	China	48.5	Severe vs. Non-severe	84 (29.2%)	24 (8.3%)	85 (29.5%)	5 (1.7%)	8 (2.8%)	0	10 (3.5%)	6 (2.1%)		
He(2) et al., 2020	95	42	53	China	57.3	Common vs. Severe vs. Critical	33 (34.7%)	8 (8.4%)	13 (13.7%)	0	0	13 (13.7%)	0	0		
Hu et al., 2020	105	43	62	China	NP	Survivors vs. Non-survivors	28 (26.7%)	4 (3.8%)	6 (5.7%)	12 (11.4%)	0	4 (3.8%)	0	6 (5.7%)		
Huang et al., 2020	54	26	28	China	41	Common vs. Severe	8 (14.8%)	5 (9.3%)	8 (14.8%)	2 (3.9%)	0	3 (5.3%)	4 (7.4%)	0		
Javanian et al., 2020	100	49	51	Iran	60.1	Deceased patients vs. Survivor patients	32 (32.0%)	37 (37.0%)	20 (20.0%)	12 (12.0%)	12 (12.0%)	3 (3.0%)	3 (3.0%)	4 (4.0%)		
Jiang et al., 2020	60	25	35	China	41	Severe vs. Non-severe	5 (8.3%)	1 (1.7%)	0	1 (1.7%)	0	0	2 (3.3%)	0		
Jin et al., 2020	45	27	18	China	58.8	Severe to critically vs. Mild to moderate	17 (37.7%)	5 (11.1%)	13 (28.8%)	3 (6.7%)	2 (4.4%)	0	0	2 (4.4%)		
Lee and Kim, 2020	51	29	22	South Korea	58	Mild vs. Severe	14 (27.4%)	8 (15.7%)	7 (13.7%)	4 (7.8%)	1 (2.0%)	0		4 (7.8%)		
Li(1) et al., 2020	548	269	279	China	60	Severe vs. Non-severe	166 (30.3%)	83 (15.1%)	34 (6.2%)	22 (4.0%)	10 (1.8%)	0	5 (0.9%)	24 (4.7%)		
Li(2) et al., 2020	312	125	187	China	69.2	Severe vs. Non-severe	178 (57.1%)	121 (38.8%)	93 (29.8%)	27 (8.6%)	10 (3.2%)	20 (6.4%)	11 (3.5%)	12 (3.8%)		
Li(3) et al., 2020	523	273	250	China	54.2	Non-ICU vs. ICU; ICU Survivors vs. ICU Non-survivors	130 (25.0%)	94 (18.0%)	38 (7.3%)	0	0	0	0	0		
Liao et al., 2020	148	74	74	China	NP	Mild or moderate progressed to severe vs. Match mild or moderate	30 (20.3%)	7 (4.7%)	7 (4.7%)	3 (2.0%)	1 (0.7%)	4 (2.7%)	0	0		
Liu(1) et al., 2020	140	91	49	China	65.5	Severe vs. Mild	63 (45%)	34 (24.3%)	35 (25%)	0	0	0	0	0		

CPD: Chronic pulmonary disease; CKD: Chronic kidney disease; CLD: Chronic liver disease; ICU: intensive care unit; NP: no performed; POTC: Patients with ordinary type of COVID-19; PSTC: Patients with severe type of COVID-19; PCTC: Patients with critical type of COVID-19. Source: author of this research, 2020.

Table 1B - Characteristics of the studies included in the meta-analyses.

Research, Society and Development, v. 10, n. 2, e50010212533, 2021 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v10i2.12533

Author		Patients		Country	Age	Groups				Comorbidi	ities			
	All	Female	Male	-	(median)		Hypertension	Diabetes	Cardiovascular disease	CPD	CKD	Cerebrovascular disease	CLD	Malignancy
Liu(2) et al., 2020	72	33	39	China	46.2	Uncomplicated Illness vs. Mild vs. Severe	7 (9.7%)	2 (2.8%)	7 (9.7%)	0	1 (1.4%)	0	0	0
Lv et al., 2020	354	179	175	China	62	Mild vs. Severe	74 (20.9%)	35 (9.9%)	18 (5.1%)	6 (1.7%)	0	0	0	2 (0.6%)
Morrison et al. 2020	81	25	56	EUA	64	Survivors vs. Non-survivors	60 (74.1%)	37 (45.7%)	23 (28.4%)	15 (18.5%)	1 (1.2%)	0	0	0
Ñamendys-Silva et al., 2020	164	50	114	Mexico	57.3	Alive vs. Dead	63 (38.4%)	53 (32.3%)	0	4 (2.4%)	6 (3.6%)	0	0	10 (6.0%)
Parra-Bracamonte et al., 2020	331,298	153,143	178,155	Mexico	44	Survivors vs. Non-survivors	66,170 (20%)	53,712 (16.2%)	7,351 (2.2%)	14,441 (4.4%)	6,895 (2.1%)	0	0	0
Rica et al., 2020	48	16	32	Spain	66	Non-ICU vs. ICU	33 (70.2%)	11 (24.4%)	14 (29.8%)	5 (10.6%)	8 (17.4%)	0	0	10 (21.3%)
Shang et al., 2020	113	40	73	China	66	Survivors vs. Non-survivors	50 (44.2%)	20 (17.7%)	28 (24.8%)	5 (4.4%)	9 (8.0%)	0	8 (7.1%)	8 (7.1%)
Shi et al., 2020	134	69	65	China	46	Severe vs. Non-severe	20 (14.9%)	9 (6.7%)	6 (4.5%)	0	0	6 (4.5%)	5 (3.7%)	5 (3.7%)
Shu et al., 2020	571	293	278	China	50	Transferred patients vs. Stable patients	55 (9.6%)	17 (3.0%)	12 (2.1%)	0	1 (0.2%)	0	0	0
Vena et al., 2020	317	104	213	Italy	71	In-hospital survivors vs. In-hospital non-survivors	149 (47%)	49 (15.5%)	63 (19.9%)	18 (5.7%)	22 (6.9%)	0	0	23 (7.2%)
Wang(1) et al., 2020	138	63	75	China	56	ICU vs. Non-ICU	43 (31.2%)	14 (10.1%)	20 (14.5%)	4 (2.9%)	4 (2.9%)	7 (5.1%)	4 (2.9%)	10 (7.2%)
Wang(2) et al., 2020	1,012	488	524	China	50	Patients with aggravation of illness during follow up vs. Patients without aggravation of illness during follow up	46 (4.5%)	27 (2.7%)	15 (1.5%)	0	0	0	0	0
Wang(3) et al., 2020	209	104	105	China	NP	Severe vs. Non-severe	27 (12.9%)	11 (5.3%)	5 (2.4%)	0	0	6 (2.9%)	0	0
Wu et al., 2020	201	73	128	China	51	With ARDS vs. Without ARDS Died vs. Alive	39 (19.4%)	22 (10.9)	8 (4.0%)	5 (2.5%)	2 (1.0%)	0	7 (3.5%)	1 (0.5%)
Xie(1) et al., 2020	79	35	44	China	60	Severe vs. Moderate	14 (17.7%)	8 (10.1%)	7 (8.9%)	0	0	0	0	0
Xie(2) et al., 2020	733	256	477	China	65	Survivors vs. Non-survivors	308 (42%)	138 (18.8%)	108 (14.7%)	37 (5.0%)	13 (1.8%)	34 (4.6%)	11(1.5%)	24 (3.3%)
Yang et al., 2020	136	70	66	China	56	Moderate vs. Severe and Critical	36 (27.1%)	20 (14.7%)	9 (6.6%)	0	4 (2.9%)	1 (0.7%)	8 (5.9%)	4 (2.9%)
Yao et al., 2020	108	65	43	China	NP	Severe vs. Non-severe Severe- alive vs. Severe-dead	16 (14.8%)	5 (4.6%)	4 (3.7%)	3 (2.8%)	0	0	2 (1.9%)	2 (1.9%)
Zhang(1) et al., 2020	140	69	71	China	57	Severe vs. Non-severe	42 (30.0%)	17 (12.1%)	7 (5.0%)	2 (1.4%)	2 (1.4%)	0	8 (5.7%)	0
Zhang(2) et al., 2020	111	65	46	China	38	Deterioration vs. Discharge	15 (13.5%)	14 (12.6%)	3 (2.7%)	3 (2.7%)	0	0	1 (0.9%)	8 (7.2%)
Zhang(3) et al., 2020	88	43	45	China	55	Moderate vs. Severe vs. Critical	23 (26.1%)	11 (12.5%)	8 (9.1%)	0	4 (4.5%)	5 (5.7%)	0	3 (3.4%)
Zheng et al., 2020	161	81	80	China	45	Severe vs. Non-severe	22 (13.7%)	7 (4.3%)	4 (2.5%)	6 (3.7%)	0	4 (2.5%)	4 (2.5%)	0
Zhou et al., 2020	191	72	119	China	56	Survivor vs. Non-survivor	58 (30.4%)	36 (18.8%)	15 (7.8%)	6 (3.1%)	2 (1.0%)	0	0	2 (1.0%)
Zhu et al., 2020	127	82	45	China	50.9	Severe vs. Non-severe	31 (24.4%)	10 (7.9%)	6 (4.7%)	6 (4.7%)	0	0	7 (5.5%)	5 (3.9%)

CPD: Chronic pulmonary disease; CKD: Chronic kidney disease; CLD: Chronic liver disease; ICU: intensive care unit; NP: no performed; POTC: Patients with ordinary type of COVID-19; PSTC: Patients with severe type of COVID-19; PCTC: Patients with critical type of COVID-19. Source: author of this research, 2020.

Seventeen studies involving 39,722 hospitalized COVID-19 patients who died and 295,500 hospitalized COVID-19 patients who recovered were included in the meta-analysis to assess the risk of death in hypertensive individuals. The pooled ORs showed that hypertensive patients hospitalized for COVID-19 had a 2.43-fold increased risk of dying (OR = 2.43 [95% CI = 1.90 - 3.11], P < 0.00001) (Table 2). The forest plot of this association is shown in Figure 3C. In this analysis, publication bias (Egger test: Z = 46.2239, P > 0.0001) and heterogeneity ($\chi 2 = 70.76$, P < 0.00001, I2 = 77%) were found (Table 2).

~	Teste of	associat	ion		Tes	te of heteroger	neity	Egge	r test
Comorbidity	OR (95% CI)	Ζ	p-value	Model	χ2	p-value	I ² (%)	Z	Р
Severity									
Hypertension	2.38(1.91-2.96)	7.83	<0.00001	R	86.94	< 0.00001	62	6.9149	< 0.0001
Diabetes	2.08(1.67-2.60)	6.52	<0.00001	R	54.21	0.01	39	5.1688	< 0.0001
Cardiovascular disease	2.36(1.98-2.80)	9.77	<0.00001	F	41.93	0.09	26	3.3947	0.0007
Chronic pulmonary disease	2.31(1.72-3.11)	5.53	<0.00001	F	19.18	0.57	0	0.8841	0.3766
Chronic kidney disease	2.55(1.11-5.84)	2.21	0.03	R	52.45	< 0.00001	69	0.6908	0.4897
Cerebrovascular disease	2.51(1.68-3.76)	4.48	<0.00001	F	10.76	0.55	0	0.1614	0.8718
Chronic liver disease	0.99(0.64-1.52)	0.06	0.95	F	13.28	0.58	0	0.3035	0.7615
Malignancy	1.40(1.00-1.96)	1.94	0.05	F	23.51	0.22	19	0.1432	0.8861
Mortality									
Hypertension	2.43(1.90-3.11)	7.05	<0.00001	R	70.76	< 0.00001	77	46.2239	< 0.0001
Diabetes	1.93(1.35-2.76)	3.62	0.0003	R	104.44	< 0.00001	85	36.2858	< 0.0001
Cardiovascular disease	2.91(2.26-3.73)	8.38	<0.00001	R	30.39	0.01	51	10.4782	< 0.0001
Chronic pulmonary disease	1.97(1.43-2.72)	4.15	<0.0001	R	23.19	0.04	44	13.3344	< 0.0001
Chronic kidney disease	3.01(1.94-4.66)	4.94	<0.00001	R	20.05	0.04	45	13.0460	< 0.0001
Cerebrovascular disease	2.40(1.60-3.60)	4.24	<0.0001	F	11.15	0.08	46	0.6710	0.5022
Chronic liver disease	1.72(0.87-3.39)	1.56	0.12	F	3.02	0.55	0	0.3098	0.7567
Malignancy	1.81(1.30-2.52)	3.52	0.0004	F	11.29	0.42	3	0.6944	0.4874

 Table 2 - Meta-analysis of association between comorbidities and severity/mortality COVID-19.

OR: odds ratio; CI: confidence interval. Source: author of this research (2020).

3.2.2. Diabetes

Thirty-four studies containing 2,501 severe and 6,567 non-severe COVID-19 patients were included in the metaanalysis to assess the susceptibility to severe form of the disease. The pooled ORs showed that diabetic patients were associated with a 2.08-fold increased risk of developing the severe COVID-19 (OR = 2.08 [95% CI = 1.67 - 2.60], P < 0.00001) (Table 2). The forest plot of this association is shown in Figure 2B. In this analysis, publication bias (Egger test: Z = 5.1688, P < 0.0001) and heterogeneity ($\chi 2 = 54.21$, P = 0.01, I2 = 39%) were detected (Table 2).

Seventeen studies were included in the meta-analysis to assess the risk of dying from COVID-19 in diabetics. Overall, 39,722 hospitalized COVID-19 patients who died and 295,500 hospitalized COVID-19 patients who recovered were analysed. The pooled ORs showed that COVID-19 patients with diabetes presented a 1.93-fold increased risk of dying (OR = 1.93 [95% CI = 1.35 - 2.76], P = 0.0003) during hospitalization (Table 2). The forest plot of this association is shown in Figure 3D. In this analysis, publication bias (Egger test: Z = 36.2858, P < 0.0001) and heterogeneity (χ 2 = 104.44, P < 0.00001, I2 = 85%) were found (Table 2).

Hypertension	Serereit					Online Radius	Outra Salar	C	Cardiorascular II.	Secondar		No. area			Celda Ratio		Crisis Rates	
Ataly of Beligtoon Charlotte et al., 2020	County 27	Yotar I	ARTER	147	2.2%	8.10, Handrides, Stille, Ch. 8.70 (0.28, 1.45)	Mitta Bendpita, 85% GL		Shally or heligroup Charloffe at al., 2020	Exects 10	40	17	147 H	8.1%	86.44, Fineral, 90% C3 0.70 (0:38, 1.840)		R.H. Faed, 1975 CF	
Chan(1) #1.8., 2020	11	32	1.0	- 24	2.1%	4.30 (1.25, 18.80)			Chenth at al. 2020	1.1	2.9	1.1	21	1.1%	2,71 (0.49, 15, 10)			
Donig et al., 2020					1.1.16	1.29.10.19.11.446			Dwng et st. 2620		- 10			14%	0.002012, 0.440	_		
Faring at al., 2020	510	+07	207	790.	5.6%	226178.2975			Flang et al. 2020	111	40.7	. 67		12.3%	2.2027 88, 8.248			
Fieng at al., 2020		124	7.8	362	4.7%	1.8211.116,2475	(marked)		Fang et al., 2020	17	124	24		5.0%	2 50 (8.27, 4.82)			
Haden of al., 2020. History at al., 2020.	41	173	126	8,76	2.4%	3-0111-38, 2.94 3-7411-37, 6.90	1000		Okiani of al., 30307.	1.0	1.73	1.14		3.1%	5382148,7388			
140K21 41 M. 2020	1.0	41	14	54	1.1 %	2.4713.04.5:00			64e(3) #1.#1, 2010	10	340	10.	259	8,5%	2.68 (5.25, 5.78)		1 1 1 1 1 1	
Hearts et al. 2020	- T	100	10	81	4.7%	1.78.01.28, 314.810			Huang of al., 2030	11	20	. r		0.7%	214(0.26, 39.43)			
Jiving et al., 2038	- T.			. 192	0.9%	1718.57,17.6%			Jan et al. 2020 Law and Firs, 2020	13	20	12		215.3	1.0014.86,1733.66; 2.2531.43,11.843			
Jim et el. 2020	32	39	1.2	. 26	1.8%	6.00 (1.58, 22.62)			5.015 of al., 2028	28	10040			1.3%	8.2912.16,73.86			
Line and kilvs, 2029 . List5 et al., 2020	104	14	11	278	1.8%	2 8 4 (2 15, 3 77) 3 21 (1 53, 3 21)			LH25 of al., 2028	45	105	47		10%	I853 80, 448			
LH25 wt st. 2028	07	105	- 91	207	4.2%	6 16 (3.46, 10.97)			LIGHT OF MIL THIRT	1.0	111	24		11.1%	0.00 (0.43, 1.8%)			
LLED # HL. 2028	40	211	- 66		1.2%	1.89 (1.13, 2.62)			Linit what , 2029	5.4	66	. 1		1.2%	2.20(0.40,10.60)			-
Liao et al., 2020	12	58	11	. 87	3.3%	3,33,018,00,3,015	the second se		Edu(1) et al., 2020	3.3	38	32	107	2.9%	2.51 (5.16, 6.62)			
Graffy et al., 2028	- 22	111	-41	107	3.2%	12111-42.7.78			List2) et al., 2029					3.5%	0.03 (8.62, 34.83)			
Lin(2) et al. 2010. Local de, 2010.	12	210	- 22	115	1.7%	3.03 (0.62, 34.93) 3.09 (0.42, 1.68)			An et al., 2020 Note et al., 2020	10	230	- 20		245	1.27 (0.44, 3.84) 1.54 (0.44, 3.42)			
Phone and all, 2018	11	240	22	27	1.1%	0.20.5X.07_1.000			Shint at 2538	102	48			0.0%	4.10 (0.72, 31.26)			
840 of al. 2036	10	48	10	0.00	0.8%	2170383,5475			Bhu H W. 2020		10			0.1%	7.77() 67, 31.82			
8to et al., 2020	· · · · · · · · · · · · · · · · · · ·	38	52	545	2.9%	3.49 (1.40.070)			Wanp(1) et al., 2020	- 0	36	11		2.7%	2.76(0).00,7.350			
Wangety at M., 2020	- 35	30	- 22	3.03	3.2%	8.0912.26,11.48			Wangero et al., 2020	2.8	100	18	812	1.2%	4.7531.86,14.138			_
Wargt2) et al., 2020	S / 2	100	40	912	3.0%	130(0.87, 3.37)			Wang(3) at al., 2020	1.1	10			0.4%	215(8.22, 23, 88)			
Wangcits at al., 2020 WALMER, 5830	-23	10	10	192	2.2%	2.0017.12.11.125	-		Wei et al., 2828	1.2	84	1.2.5		1.5%	2.41 (0.64, 10.36)			
its et al., 3920		- 29	10		2.8%	0.001010.2.420	the second se		10e et al., 2020	100	29			2.0%	8.71 (11:13:331)			
Yong at al., 2020	17	3.9	19	102	2.1%	47012.01.19.94	and the second se		Yang et al., 2020 Yang et al., 2020	- 22	200	- 2		0.7%	3141 (1.74, 11.57) 1152 (0.47, 34.34)			
Yau et al., JUDD		-38	1.1	#3	3.8%	6.1113.88,10.82			Zhengell et al., 2020	100	50	5	8	14%	1.95 (8.42, 9.67)			
Storeg(1) et al., 2020	22	10	- 30	83	1.9%	180281,344			Thirty(1) #1-4, 2020	1.1	10	1			11.MI(0.56, 1.34.40)		-	
2hang(3 et el., 2020 Zhang(3 et el., 2020		10	2	- 83 39	1.3%	2270 (6.83, 60.32)			2horig(3) et al., 2020	1.1	59		28	0.7%	3.7118.44, 33.210			
Driving of al., 2010	14	- 10	10	1.21	27%	8.8713.84, 31-37	and the second sec		Driving et al., 2020		388	- 7		0.4%	4.61 (0.82, 34.11)			
27m at at 2020		16	52	111	2.4%	3.83 (5.38, 11, 29)			200 et el. 2030		10		.111	0.5%	3192 (0.64, 22.81)		1000	
Turnel (195%) CB		2504		6567	100.0%	2.36 (1.04, 2.04)	•		Toroni (097% CE		2412		8401 N	86.8%	2.34 (1.64, 2.40)		•	
Total animals			1202				1992 A		Total events			711					10855	
			33.00	0.0000	11.1-42	6. ·	kar and the rad		inteleropeneity Chillin 8			16、产业 2月	1.46			0.01 8.1		10
Litsterogenativ Tau ⁴	+ 0.22, Chiff+	100.04.18																
	0.20, ChP+ (#>730) (P	D.0000003	1				Family (1) Family (1) (1)		Test for overall effect 2	- 111 11 11	0.00001)						market. Consum 2007	ninolii.
Listerogenativ Tau ⁴ Test for smeat effect	+ 0.22, ChiP+ (2 + 7 3/3 (P -	· D.000003)	1				Famult Inperchantel, Famult (ortine)		Test for overall effect 2	- 1.77 (* -	0.00001)						metal Canera 207	ninolij.
Heaterogeneite Taur Teat for seecal affect Diabeter	an tai p	- 5.00000)				Ooks Rates	Famati (operchante) Famali (control) Onto Neto	n	Chronic Pulmonary D		nical	Nov. 107			Odds Rate	Fainten (sigar)	Other Ratter	rifoeli
Historogenady: Tash Yash ka sooraa affect Diabetee Blady of Boltgroup	Savereis Events	Total	Nue ant	Total	Worght, 7	Data Rain K.n. Ravenes, 1911, Cl	Famult Inperchantel, Famult (ortine)	n			nical		Total V	Weight	Odds Ratte M-R, Fixed, 19% CI	Fainten (sigar)		nikolij.
instanogenanty TauP Yost für sonrall affect Diabeten Abady oc Beligtinge Charloffe at al., 2020	Savereis Events	- 5.00000)		Total	Weight 1	Data Rain K.n. Raedset, 101, CJ 9.75 (J.15, 1.03)	Famati (operchante) Famali (control) Onto Neto	D	Chronic Pulaeoury D Study of Subgroup	. Seenieks	rtical Total E	Sventa	7/10/ 9		M-H, Fixed, 95% CI	Fainten (sigar)	Other Ratter	nikolij.
Historogenady: Tash Yash ka sooraa affect Diabetee Blady of Boltgroup	Severals Freedo	10,00000) Total 45 27 0	Austan Internetia 4 2	143 143 21 8	Worght 1 4.5% 21% 1.2%	00048 Ratio 6.m. Ratedons, Mith. O. 8.7% 82.1%, 1.400 1.7% 93.44, 7.620 1.000 14, 12.440	Famati (operchante) Famali (control) Onto Neto	D	Chronic Pulseowary D Study of Subgroup Chartothe et al., 2020	. Seenieks	rtical Totat 8 49		79806 W	9.0%	M-H, Fixed, 95% Ci 1.45 (0.45, 4.27)	Fainten (sigar)	Olds Ratte FR, Fixed, 95% CI	14006
Instanceparently: TasP Tast for sense at deter Marky of Redigment Charlotte at at., 2020 Charlotte at at., 2020 Diverset) at at., 2020 Diverset) at at., 2020	Secure Events 1 1 1 1 1 1 0 1 0 0	10,00000) Total 1 450 277 0 407	41 41 2 01	147 147 21 8 792	44% 21% 13% 9.2%	Doble Ratio 6.0, Racescel, Vith, D. 8.76 (8.36, 1.69) 1.76 (8.36, 1.69) 1.76 (8.36, 1.69) 1.76 (8.36, 1.24) 1.62 (1.31, 1.24) 1.62 (1.31, 2.44)	Famati (operchante) Famali (control) Onto Neto	D	Chroak: Polasseary D Study of Subgroup Chartolle et al., 2020 Cherc(1) et al., 2020	. Seenieks	rttical Total 8 49 27	Sventa	79808 W 147 21	9.0% 2.0%	M-H, Fixed, 95% CI 1.45 (3.45, 4.27) 0.77 (0.85, 13.87)	Fainten (sigar)	Olds Ratte FR, Fixed, 95% CI	r#coli)
Intercoperative Tast* Triat for several affect Blade for Mady of Bellational Cherical et al., 2020 Cherical et al., 2020 Fange et al., 2020 Fange et al., 2020	500000000 5000000 500000 11 0 0 0 0 0 0	*0.00003) ************************************	41 4 2 01 12	Total : 147 21 8 295 3952	Wonght 1 4.5% 2.1% 1.3% 0.2% 3.2%	Doble Ration #16, Ratediots, VMA (2) #75 83.35, 7.60 1.76 93.45, 7.62 (50 87.15, 12.40) 1.62 11.23, 2.46 U.86 93, 2.66 U.86 93, 2.66	Famati (operchante) Famali (control) Onto Neto	D	Chronic Polarowary D Study of Subgroup Chartolle et al., 2020 Cherry(1) et al., 2020 Dang et al., 2020	5 Severals Events 5 1 2	Tical Totat 8 49 27 0	tt 1 1 1	79808 W 147 25 8	9,0% 2,0% 1,5%	M-H, Fixed, 95% CI 1.40 (0.46, 4.37) 0.77 (0.95, 13.07) 2.00 (0.15, 27, 45)	Fainten (sigar)	Onde Ratio	
Intelecoperantly: TapP Triabilities Blady of Bellightnee Charlotte at al., 2020 Cherry(1 et al., 2020 Freng et al., 2020 Freng et al., 2020 Freng et al., 2020	Secure Events 1 1 1 1 1 1 0 1 0 0	- 5.00000) - 5.00000) - 50000 - 50000 - 50000 - 500000 - 5000000 - 5000000 - 50000000 - 50000000 - 50000000 - 50000000 - 50000000 - 50000000 - 5000000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 500000 - 50000 - 500000 - 500000 - 500000 - 50000 - 500000 - 500000 - 50000 - 50000 - 50000 -	41 41 2 01	Total : 147 21 8 292 392 922 626	Weight 1 4.5% 2.1% 1.2% 4.2% 4.2% 4.7%	Onto Ratio Rev. Resolution (1996) C2 87/5 B 255, 1 400 1 7/5 (3 49, 7/52) (50 (2 11, 21, 2 40) 1 4/2 (11, 21, 2 40) 1 4/2 (11, 21, 2 40) 3 3 40 (1 40), 5 1 40 3 3 40 (1 40), 5 1 40	Famati (operchante) Famali (control) Onto Neto	D	Chroak: Polasseary D Study of Subgroup Chartolle et al., 2020 Cherc(1) et al., 2020	. Seenieks	rttical Total 8 49 27	Sventa	79808 W 147 25 8	9.0% 2.0%	M-H, Fixed, 95% CI 1.45 (3.45, 4.27) 0.77 (0.85, 13.87)	Fainten (sigar)	Olds Ratte FR, Fixed, 95% CI	
Intercoursely: Tach Text for some at effect Hade to: Made or Belgering Charlotte et el., 2020 Deng et el., 2020 Dang et el., 2020 Dang et el., 2020 Dang et el., 2020 Dang et el., 2020	500000000 5000000 500000 11 0 0 0 0 0 0	10.000000) 10.0000001 10.000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.0000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.000001 10.0000001 10.0000001 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.0000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.000000 10.0000000 10.00000000 10.0000000000	41 41 42 01 122 13 2 2 32	Tutat 147 21 80 290 392 920 54	Wataht 1 4.6% 2.1% 1.2% 0.2% 0.2% 0.2%	Obbie Raim 8.46, Raidords, Mith, C2 8.76 (82.35, 1.66) 1.76 (82.35, 1.66) 1.60 (1.61, 12.46) 1.62 (1.31, 22.46) 1.62 (1.	Famati (operchante) Famali (control) Onto Neto	D	Chreak Polassary I Study of Subgroup Chartotle et al., 2020 Cherry(1) et al., 2020 Dang et al., 2020 Flang et al., 2020	5 Severals Events 5 1 2	Tical Totat 8 49 27 0	tt 1 1 1	79808 W 147 25 8	9,0% 2,0% 1,5%	M-H, Fixed, 95% CI 1.40 (0.46, 4.37) 0.77 (0.95, 13.07) 2.00 (0.15, 27, 45)	Fainten (sigar)	Onde Ratio	
Intercorrently Tech Test for several affect Blady or Bellgroue Charolite at al., 2020 Cherolite at al., 2020 Deng et al., 2020 Peng et al., 2020	500000000 5000000 500000 11 0 0 0 0 0 0	- 5.00000) - 5.00000) - 50000 - 50000 - 50000 - 500000 - 5000000 - 5000000 - 50000000 - 50000000 - 50000000 - 50000000 - 50000000 - 50000000 - 50000000 - 5000000 - 50000000 - 50000000 - 50000000 - 500000000 - 500000000 - 5000000000 - 500000000000000 - 5000000000000000000000000000000000000	41 4 2 01 12	Tubat 147 21 8 2952 3852 654 258	Weight 1 4.5% 2.1% 1.2% 4.2% 4.2% 4.7%	Odola Rasim Ris, Rasolicia, Vitto C2, 87.76 83.45, 1.500 1.76 93.45, 7.502 1.602 11, 23, 3.482 1.602 12, 20, 3.482 1.602 12, 5.482 1.602 1	Famati (operchante) Famali (control) Onto Neto	D_	Chreak Polisivery I Study of Subgroup Chartotle et al., 2628 Chern(1) et al., 2628 Dang et al., 2020 Fang et al., 2020 Fang et al., 2020	5 5 1 2 70 14	Tical Total 8 49 27 9 467 124	11 1 1 18 8	147 21 8 793 352	9.0% 2.0% 1.5% 21.4% 6.8%	M-H, Fixed, 95% CI 1.40 (0.46, 4.27) 0.77 (0.95, 13.07) 2.00 (0.15, 27.45) 3.09 (1.07, 4.95) 5.47 (2.24, 13.39)	Fainten (sigar)	Onde Ratio	
Intercorrently Tech Test for some affect Black or Bellground Charolis at al., 2020 Cherolis et al., 2020 Dang et al., 2020 Pang et al., 2020	500000000 5000000 500000 11 0 0 0 0 0 0	*D.000001) *D.000000000000000000000000000000000000	41 41 42 01 122 13 2 2 32	147 147 24 292 292 292 292 292 292 292 292 292	Winisht 1 4.5% 2.1% 2.2% 4.5% 4.5% 4.5% 4.5% 4.5%	Costo Ruster 8.6, Raselous, Mrs. Cl. 8.75 B. 25, 148 1.75 B. 24, 124 1.65 B. 4, 124 1.62 B. 25, 248 1.62 B. 25, 248 1.62 B. 25, 248 1.62 B. 25, 210 1.62 B. 25, 210 1.65 B. 25, 210 1.	Famati (operchante) Famali (control) Onto Neto	D_	Chronic Polisionary I Study of Subgroup Crustoffe et al., 2020 Cherry(1) et al., 2020 Plang et al., 2020 Plang et al., 2020 Ouer at al., 2020 Ouer at al., 2020	5 Seeare/ct 5 5 1 2 2 70	Tiotat 8 49 27 9 467 124 175	11 1 1 18	1410 ¥ 147 21 8 783 352 828	9.0% 2.0% 1.5% 21.4% 6.8% 3.3%	M-H, Flood, 95% CT 1.40 (3.46, 4.37) 0.77 (3.95, 13.07) 2.00 (3.15, 27.45) 2.00 (7.17, 4.95) 5.47 (2.24, 13.39) 5.51 (1.78, 17.20)	Fainten (sigar)	Onde Ratio	
Intercoperativ Tau? Text Rar weeks after Blady or Bellgring Environment at 2010 Chevrol et al., 2010 Arrag et al., 2010 Arrag et al., 2010 Arrag et al., 2010	500000000 5000000 500000 11 0 0 0 0 0 0	- 5.000001) - 705001 - 705000 - 7050000 - 705000 - 705000 - 705000 - 705000 - 705000 - 705000 -	41 41 42 01 122 13 2 2 32	143 143 21 202 202 202 54 250 54 250 82 55 250	Winight) 4.5% 2.1% 1.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2%	Cobies Reem #10, Reardows, 5705 (2) #716 (2) JK, 1 406 (4) (2) (2) (2) (2) (2) (4) (2) (2) (2) (2) (2) (4) (2)	Famati (operchante) Famali (control) Onto Neto	D _	Chrinels Polisionary II Study of Subgroup Chierkete et al., 2020 Chierkete et al., 2020 Dang et al., 2020 Fang et al., 2020 Fang et al., 2020 Hech et al., 2020 Hech et al., 2020	5 5 1 2 70 14	Tiotat 8 49 27 9 467 124 173 30	11 1 1 18 8	1400 ¥ 147 21 8 793 352 828 258	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1%	M-H, Fixed, 1974 CI 1.40 (3.46, 4.27) 0.77 (3.86, 13.87) 2.00 (3.15, 27, 45) 2.00 (7.07, 4.95) 5.47 (2.24, 13.38) 5.53 (7.224, 13.38) 6.53 (7.17, 17.20) 6.107 (2.87, 37.90)	Fainten (sigar)	Onde Ratio	
Intercoperative Tau-7 fault for several affect Diskbore Handy of Bullgetree Charlotte at al., 2020 District at al., 2020	500000000 5000000 5000000 11 11 10 10 10 10 10 10	- 0.000001) - 70404 (1) - 704	1000 000 000 000 000 000 000 000 000 00	**** Tobal 147 21 8792 2922 2922 2923 292 292 292 292	Windot 1 21% 21% 12% 82% 12% 82% 12% 12% 12%	Dobin Rusin 6.0, Raseburg, Urin, CJ 6.75 B. 25, 140 1.75 B. 24, 124 1.65 B. 24, 245 1.65 B.	Famati (operchante) Famali (control) Onto Neto	D _	Chronic Pulanonary II Study of Subgroup Chardollis et al., 2020 Chardollis et al., 2020 Dang et al., 2020 Fang et al., 2020 Ouan et al., 2020 Decigi et al., 2020 Decigi et al., 2020 HeCD et al., 2020	5 5 1 2 70 14	Trical Total 6 49 27 9 467 124 173 30 3	11 1 1 18 8	141 21 8 783 352 828 258 51	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1% 0.6%	M-H, Fixed, 95% CI 1.40 (3.46, 4.27) 0.77 (0.05, 13.07) 2.00 (0.15, 27.45) 3.06 (1.07, 4.05) 5.47 (2.24, 13.30) 5.51 (1.74, 17.20) 2.63 (0.17, 07, 4.05) 2.63 (0.17, 07, 4.05) 2.63 (0.17, 07, 07, 07) 2.63 (0.17, 07, 07)	Fainten (sigar)	Onde Ratio	
Inter-Cognitive Turk- Fred for ownear effect Mada or Delignmen Character et al. 2020 Chercol et al. 2020 Chercol et al. 2020 Grang et al. 2020 Grang et al. 2020 Grang et al. 2020 House et al. 2020 Marce et al. 2020 Anna et al. 2020	Beentreit Freedor 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 0.000001) - 0.000001) - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	4 4 2 0 12 (2 2 1 5 1 2 4 1	Total 147 21 8 29 302 626 54 55 825 82 50 82 51 82 20 37 270	Weight) 4.5% 21% 1.22% 6.127% 6.127% 6.127% 6.27% 1.27% 6.27%	Control Reserve #10, Reserve #176 ED	Famati (operchante) Famali (control) Onto Neto	D _	Chrinels Polisionary II Study of Subgroup Chierkete et al., 2020 Chierkete et al., 2020 Dang et al., 2020 Fang et al., 2020 Fang et al., 2020 Hech et al., 2020 Hech et al., 2020	5 5 1 2 70 14	Trical Total 8 49 27 0 467 124 173 30 3 0	11 1 1 18 8	141 21 8 783 352 828 51 52	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1%	M-H, Fixed, 1974 CI 1.40 (3.46, 4.27) 0.77 (3.86, 13.87) 2.00 (3.15, 27, 45) 2.00 (7.07, 4.95) 5.47 (2.24, 13.38) 5.53 (7.224, 13.38) 6.53 (7.17, 17.20) 6.107 (2.87, 37.90)	Fainten (sigar)	Onde Ratio	
Intercopresely Tach- Tost for exercise effect Nada or for an effect Connector and a connector Connector and a connector Connector and a connector Forma of al. 2020 Connector and a connector forma and a connector Presca and a connector Names and Anno 2020 Connector Names and Anno Anne and Anno 2020 Units of a 2, 2020	500 100 100 100 100 100 100 100 100 100	- 0.000001) - Total 1 - Total 1 - 40 - 27 - 27 - 40 - 75 -	41 2 11 2 2 11 2 4 3 12	Total 147 21 8 29 20 20 20 58 20 58 20 58 20 58 20 52 20 20 20 20 20 20 20 20 20 20 20 20 20	Winaht 1 4.5% 212% 4.27% 4.27% 4.27% 4.27% 4.27% 8.27%	Option Rearies Mins, Rear Prices, 1970; C. D. 1776; D. K. 1976; A. K. 1976; 1776; D. K. 1976; A. K. 1976; 1760; D. K. 1976; A. K. 1976; 1760; D. K. 1976; A. K. 1976; 1760; D. K. 1977; 1760; D. K. 1976; 1760; D. K.	Famati (operchante) Famali (control) Onto Neto	D_	Chronic Pulanonary II Study of Subgroup Chardollis et al., 2020 Chardollis et al., 2020 Dang et al., 2020 Fang et al., 2020 Ouan et al., 2020 Decigi et al., 2020 Decigi et al., 2020 HeCD et al., 2020	5 5 1 2 70 14	Trical Total 6 49 27 9 467 124 173 30 3	11 1 1 18 8	141 21 8 783 352 828 258 51	9.0% 2.0% 1.5% 6.8% 3.3% 1.1% 0.6% 0.8%	M-H, Fixed, 95% CI 1.40 (3.46, 4.27) 0.77 (0.05, 13.07) 2.00 (0.15, 27.45) 3.06 (1.07, 4.05) 5.47 (2.24, 13.30) 5.51 (1.74, 17.20) 2.63 (0.17, 07, 4.05) 2.63 (0.17, 07, 4.05) 2.63 (0.17, 07, 07, 07) 2.63 (0.17, 07, 07)	Fainten (sigar)	Onde Ratio	
Inductory when Turk's Track for means a default Track for means a default Track for means a default Track for means a default Character M. 1920 Character M. 1920 Track for M. 192	Beentreit Freedor 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	- 0.000001) - 0.000001) - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	4 4 2 0 12 (2 2 1 5 1 2 4 1	Total 147 21 8 29 302 626 54 55 825 82 51 82 20 52 20 37 270	Weight) 4.5% 21% 1.22% 6.127% 6.127% 6.127% 6.27% 1.27% 6.27%	Control Reserve #10, Reserve #176 ED	Famati (operchante) Famali (control) Onto Neto	D _	Chronic Polanowary II Study of Subgroup Cherry(1 et al., 2020 Cherry(1 et al., 2020 Cherry(1 et al., 2020 Fang et al., 2020 Fang et al., 2020 Houng et al., 2020 Houng et al., 2020 Jamp et al., 2020 Jamp et al., 2020	5 5 1 2 70 14	Tical <u>Total 1</u> 40 27 0 407 124 173 36 3 0 20	11 1 1 18 8	147 147 21 8 783 352 828 258 51 52 25	9.0% 2.0% 1.5% 21.4% 6.3% 3.3% 1.1% 0.6% 0.8% 0.7%	M-H, Fixed, 1954 CI 1.45 [3.46, 4.27] U.77 [0.06, 13.07] 2.00 [0.15, 27, 45] 3.69 [1.97, 4.33] 5.47 [2.34, 13.38] 5.51 [2.34, 13.38] 4.67 [0.87, 37.90] 2.69 [0.16, 277, 10.00] 2.09 [0.56, 270.00] 2.09 [0.56, 270.00]	Fainten (sigar)	Onde Ratio	
Instructure and the second states of the second state of the s	500 100 100 100 100 100 100 100 100 100	*0.000001) *000001 (1 *0000 (1 *000 *0	41 2 11 2 2 11 2 4 3 12	147 147 21 302 302 302 302 302 302 302 302 302 302	WHILE A STATE	Dabb Ram M. Barelos, Mito. 20 1798 A4, 709 1798 A4, 709 1798 A4, 709 160 B1 (4, 1246) 160 B1 (4, 1246) 150 B1 (4, 1147) 150 B1 (4,	Famati (operchante) Famali (control) Onto Neto	D_	Chronic Polanowaty D Staty of Subgroup Cherchie et al., 1021 Cherchi et al., 2020 Cherchi et al., 2020 Fang et al., 2020 Fang et al., 2020 Fang et al., 2020 HecQi et al., 2020 HecQi et al., 2020 Jamp et al., 2020 Jamp et al., 2020 Jamp et al., 2020	5 Securita/12 5 1 2 20 14 8 2 0 0 0 3 2 7	Tical <u>Total 1</u> 40 27 0 407 124 173 30 3 0 20 14	11 1 1 18 8	Total V 147 147 18 793 793 352 828 51 52 258 51 52 25 37	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1% 0.6% 0.6% 0.5% 1.7%	M-H, Fixed, 65A Ci 140 (J.44, 4.27) 0.77 (J.36, 13.87) 2.00 (J.15, 27, 48) 2.00 (J.17, 27, 48) 5.47 (J.24, 13.30) 5.47 (J.24, 13.30) 6.17 (J.17, 30, 17.30) 2.03 (J.17, 71.40) 2.03 (J.17, 71.40) 2.02 (J.08, 53.77) 0.28 (J.27, 73.44)	Fainten (sigar)	Onde Ratio	
Intercopreter Tard T Trait for invested affect III.J. Level Marks of Interprint Charloss et al., 2020 Deng et al., 2020 Tard Star, 2020 Tard Star, 2020 Tard Star, 2020 Heng et al., 2020 Link et al., 2020	Execution Eventself	- 0.000001 - 704al 1 - 704al 1	41 4 2 0 12 5 2 2 3 1 2 4 3 12 0 3	147 147 21 2102 2002 2009 54 2009 55 2019 2019 2019 2019 2019 2019 2019 2019	Windows 在台湾、 1.2.2% 1.2% 1	Datab Harm Hin, Research, 19th, O. 27 Hill, M. K. 1089 1, Fille M. K. 1089 1, Fille M. K. 1089 1, Fille M. K. 1089 1, Fill H. K. 1089 1, June H.	Famati (operchante) Famali (control) Onto Neto	D _	Chronic Publishmenty D Sharty of Subgroups Churchdle et al., 2020 Charg Cit al., 3020 Paring et al., 2020 Paring et al., 2020 Ouan et al., 2020 Ouan et al., 2020 Anity et al., 2020 Anity et al., 2020 Anity et al., 2020 Line and Non, 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	mical <u>Total</u> (49 27 9 467 124 173 30 3 8 20 14 269	tt 11 10 8 8 3 2 1 0 2 8	71400 ¥ 147 21 8 793 352 828 828 828 828 82 828 82 82 82 82 82	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1% 0.8% 0.8% 0.7% 1.7%	M-H, Fixed, 1955 CI 1.45 [3.48, 4.27] U.77 [3.08, 13.07] 2.69 [2.15, 27, 45] 3.06 [7.17, 4.05] 5.47 [2.34, 13.08] 5.51 [1.70, 17, 37.05] 4.07 [9.57, 37.05] 2.02 [0.08, 53.77] 10.29 [0.52, 210.08] 2.35 [0.37, 23.04] 2.35 [0.37, 23.04] 2.35 [0.37, 23.04] 2.35 [0.37, 23.04] 3.51 [1.7, 47]	Fainten (sigar)	Onde Ratio	
Intercourselv Tury, Final Fur seemail affect Illubreter Illubre	Los 7 201 (P Executive Executive 11 0 0 0 0 0 0 0 0 0 0 0 0 0	-0.000001 -0.000001 -0.000001 -0.00000 -0.00000 -0.00000 -0.000000 -0.0000001 -0.00000001 -0.0000001 -0.0000001 -0.0000000 -0.000000 -0.000000 -0.000000 -0.00000 -0.00000 -0.000000 -0.000000 -0.00000 -0.000000 -0.000000 -0.000000 -0.000000 -0.000000 -0.000000 -0.000000 -0.0000000 -0.0000000 -0.0000000 -0.0000000 -0.0000000 -0.0000000 -0.0000000 -0.00000000 -0.0000000 -0.0000000 -0.0000000 -0.0000000 -0.0000000 -0.00000000 -0.0000000000	41 4 2 0 12 5 2 2 3 1 2 4 3 12 0 3	147 147 21 292 292 292 292 292 292 295 205 205 205 205 205 205 205 205 205 20	WHERE 4 2 1 2 2 4 4 5 5 5 1 2 2 4 5 5 5 5 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 5 7 7 7 5 5 7 7 7 5 5 7 7 7 5 5 7 7 7 5 5 7 7 7 7 5 5 7	Data Rate 66, Resolve, 101, O. 275, B. J. (1997) 101, S. (1997) 10	Famati (operchante) Famali (control) Onto Neto	D	Chronic Polisionary D Study of Soldprom Chronic Mark 41, 2020 Cherry et al., 2020 Faring et al., 2020 Faring et al., 2020 Faring et al., 2020 Faring et al., 2020 HerCl et al., 2020 HerCl et al., 2020 Law and AL, 2020	5 Securita/12 5 1 2 20 14 8 2 0 0 0 3 2 7	mical <u>Total</u> (49 9 467 124 173 30 3 0 20 14 269 105	11 1 1 18 8	71400 ¥ 147 21 8 793 352 828 828 828 828 828 828 828 827 258 25 379 287	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1% 0.6% 0.6% 0.7% 1.7% 10.1% 17.7%	M-H, Fixed, 95% CI 1.46 [0.46], 4.27 0.77 [0.16], 1.367 2.06 [0.15], 27.405 5.47 [2.24, 13.30] 5.51 [1.76], 17.20 4.67 [0.97, 27.455 2.43 [0.16], 17.30 4.67 [0.97, 27.455 2.43 [0.16], 27.47 2.43 [0.17], 27.485 2.43 [0.17], 27.485 2.45 [0.17], 27.485	Fainten (sigar)	Onde Ratio	
Intercopresents Tary Total for several dent Status for several dent Status of temperature Cranetons at a, 2020 Cranetons at a, 2020 Frage at a, 2020 Frage at a, 2020 Neuron de A, 2020 Severa de	Execution Eventself	- 0.000001 - 700401 - 70040 - 700 - 700	41 4 2 0 12 5 2 2 3 1 2 4 3 12 0 3	**** Total 14.7 21 8 202 205 54 205 205 205 207 207 207 207 207 207 207 207	Windows 2010 1225 1225 1225 1225 1225 1225 1225	Conta Rate: 10. Association, 10. CO. 1. Phys. Rev. 7 (2) 1. Phys. Rev. 7 (2) 1. Phys. Rev. 7 (2) 1. Conta Rev. 7 (2) 2. Conta Rev	Famati (operchante) Famali (control) Onto Neto	D	Chronic Publishmenty D Sharty of Subgroups Churchdle et al., 2020 Charg Cit al., 3020 Paring et al., 2020 Paring et al., 2020 Ouan et al., 2020 Ouan et al., 2020 Anity et al., 2020 Anity et al., 2020 Anity et al., 2020 Line and Non, 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	mical <u>Total</u> (49 27 9 467 124 173 30 3 8 20 14 269	tt 11 10 8 8 3 2 1 0 2 8	71400 ¥ 147 21 8 783 352 828 828 828 828 827 258 827 379 217	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1% 0.8% 0.8% 0.7% 1.7%	M-H, Fixed, 1955 CI 1.45 [3.48, 4.27] U.77 [3.08, 13.07] 2.69 [2.15, 27, 45] 3.06 [7.17, 4.05] 5.47 [2.34, 13.08] 5.51 [1.70, 17, 37.05] 4.07 [9.57, 37.05] 2.02 [0.08, 53.77] 10.29 [0.52, 210.08] 2.35 [0.37, 23.04] 2.35 [0.37, 23.04] 2.35 [0.37, 23.04] 2.35 [0.37, 23.04] 3.51 [1.7, 47]	Fainten (sigar)	Onde Ratio	
Intercopresent Tury, Tur	Execution Eventself	-0.000001) -70484 1 40 27 40 173 40 173 40 173 40 173 40 173 40 173 40 173 40 173 40 173 40 173 40 173 14 200 114 200 201 114 200 201 114 200 201 114 200 201 201 201 201 201 201 201	4 4 2 0 12 0 2 0 3 4 3 4 1 2 0 3 1 3 8 3 5 1 3 8 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	14/1 14/1 21 21 21 21 21 21 21 21 21 21 21 21 21	Window 2196 2296 2296 2296 2296 2296 2296 2296	Datab Harm M. Resolut, 1915, D. 2019, B. 44, 1.06 1.01, 1.01, 2.04 1.01, 1.01, 1.01, 2.04 1.01, 1	Famati (operchante) Famali (control) Onto Neto	D _	Chronic Polisionary D Study of Soldprom Chronic Mark 41, 2020 Cherry et al., 2020 Faring et al., 2020 Faring et al., 2020 Faring et al., 2020 Faring et al., 2020 HerCl et al., 2020 HerCl et al., 2020 Law and AL, 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	mical <u>Total</u> (49 9 467 124 173 30 3 0 20 14 269 105	tt 11 10 8 8 3 2 1 0 2 8	71400 ¥ 147 21 8 793 352 828 828 828 828 828 828 828 827 258 25 379 287	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1% 0.6% 0.6% 0.7% 1.7% 10.1% 17.7%	M-H, Fixed, 95% CI 1.46 [0.46], 4.27 0.77 [0.16], 1.367 2.06 [0.15], 27.405 5.47 [2.24, 13.30] 5.51 [1.76], 17.20 4.67 [0.97, 27.495 2.43 [0.16], 7.17.30 2.43 [0.17], 71.68 2.43 [0.16], 27.47 2.43 [0.17], 71.68 2.43 [0.17], 71.68 2.43 [0.17], 71.68 2.43 [0.17], 71.68 2.43 [0.17], 71.68 2.43 [0.17], 71.68 2.45	Fainten (sigar)	Onde Ratio	
Instructure and the second states of the second sta	Execution Eventself	- 0.000001 - 700401 - 70040 - 700 - 700	41 4 2 0 12 5 2 2 3 1 2 4 3 12 0 3	1410 1421 1421 1421 1422 1422 1422 1422	Window 2196 2296 2296 2296 2296 2296 2296 2296	Data Rate and Reveal and Second Second 1.798 Automatic Second Second Second 1.798 Automatic Second Secon	Famati (operchante) Famali (control) Onto Neto	D _	Christic Fuldamenty D Starty of Subgroup Christic et al., 2020 Chert(H et al., 2020 Chert(H et al., 2020 Dang et al., 2020 Dang et al., 2020 Dealer et al., 2020 Dealer et al., 2020 Dealer et al., 2020 Dealer et al., 2020 Lift) et al., 2020 Lift et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Tical Total (40 27 0 407 124 173 30 3 0 3 0 124 173 30 3 0 14 209 14 209 14 209 15 20 20 20 20 20 20 20 20 20 20	tt 11 10 8 8 3 2 1 0 2 8	7444 V 147 21 147 21 147 25 258 57 258 57 258 379 225 379 225 379 225 379 225 115	9.0% 2.0% 1.5% 21.4% 6.8% 3.3% 1.1% 0.6% 0.6% 0.6% 1.7% 10.1% 17.1% 2.7% 4.9%	M-R, Flued, 1954; CJ 1.46 (0.48, 4.377) 2.06 (1.47, 10.84, 13.07) 2.06 (1.47, 20.48, 13.07) 2.06 (1.47, 20.48, 13.07) 5.47 (1.07, 4.05) 5.47 (1.07, 4.05) 2.48 (1.07, 10.77, 20.90) 2.48 (1.07, 10.77, 20.90) 2.48 (1.07, 10.90) 2.49 (1.04, 10.97) 2.49 (1.04, 10.97) 3.40 (1.04,	Fainten (sigar)	Onde Ratio	
Intercopretative Turk, Total Fur sense at their Tataly, or Sense at their Tataly, or Sense at the Tataly, or Sense at Tataly, or Sense at Tata	Execution Eventself	- 0.000001 - 75400 1 - 75400 1	11111111111111111111111111111111111111	1010 1017	Windows 有有效。 有有效。 有有效。 有有效。 有有效。 有有效。 有有效。 有有效	Datab Rate: 66, Resolve, 101: O. 87, Fill and S. (1995) 1975; B. J. (1995) 1975; B. J. (1995) 1987; B. J. (1995) 1997; B	Famati (operchante) Famali (control) Onto Neto	D _	Christic Foldonistry D Christic of Subgroup Christoff of Subgroup Christoff et al., 2020 Drang et al., 2020 Drang et al., 2020 Fang et al., 2020 Drang et al., 2020 Drang et al., 2020 Husing et al., 2020 Jump et al., 2020 Jump et al., 2020 July of al., 2020 Lizly et al., 2020 Lizle et al., 2020 Roca et al., 2020 Roca et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Tical Total (40 27 0 407 124 173 30 3 0 20 14 269 105 566 126 20 20 20 20 20 20 20 20 20 20	tt 11 10 8 8 3 2 1 0 2 8	Tentor W 147 21 18 793.3 352 838 51 52 52 379 3297 92 115 37	9,0% 2,0% 1,5% 21,4% 6,3% 3,3% 1,1% 0,5% 0,7% 1,7% 10,1% 10,1% 10,1% 5,9%	Mill, Freed, 1954; G. 7 1.40 (Ja 44, 4.27) 2.00 (Ja 7, 10.06, 13.07) 2.00 (Ja 7, 20.06) 5.47 (J. 20.4, 13.07) 5.47 (J. 20.4, 13.07) 5.48 (J. 10.17, 13.07) 5.49 (J. 10.17, 13.07) 5.47 (J. 10.17, 13.0	Fainten (sigar)	Onde Ratio	
Intercoursely Taylor Ta	23 7 200 (P Severate Freedor 11 1 1 1 1 1 1 1 1 1 1 1 1	- 0.000001 - 700401 1 - 7004	1 + 2 + 2 + 2 + 2 + 2 + 2 + 2 + 2 + 2 +	Total 14.1 14.7 21 22 282 282 284 291	Windows 是211年後期 221日時期 121日日 121日 121日日 121日日 121日日 121日日 121 121	Control Region March Research, M. 1999, C. 1999	Constanting Passada gommag	D	Christik Politowstry II Stady of Subgetop Christike et al., 3520 Christike et al., 3520 Christike et al., 3520 Dang stal., 2020 Fang et al., 2020 Data et al., 2020 HeiCB et al., 2020 HeiCB et al., 2020 HeiCB et al., 2020 HeiCB et al., 2020 Life et al., 2020 Life et al., 2020 HeicH et al., 2020 HeicH et al., 2020 HeicH et al., 2020 HeicH et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	mical <u>Total</u> 1 49 27 9 407 124 173 30 3 10 20 14 265 165 566 236 26 36	tt 11 10 8 8 3 2 1 0 2 8	Tentor W 147 21 18 793.3 352 838 51 52 52 379 217 92 115 27 102 27	9,0% 2,0% 1,5% 21,4% 6,3% 3,3% 1,1% 0,5% 0,5% 0,7% 1,7% 10,5% 12,7% 4,9% 5,9% 0,9%	<u>M.H. (1996)</u> , 140 , 144 , 4 , 327 , 140 , 144 , 4 , 327 , 177 , 1206 , 175 , 277 , 4206 , 547 , 172 , 4216 , 547 , 1726 , 437 , 1736 , 437 , 1736 , 437 , 1736 , 437 , 1736 , 439 , 1737 , 1736 , 239 , 1038 , 5377 , 144 , 1532 , 3175 , 442 , 543 , 3175 , 443 , 543 , 3175 , 444 , 543 , 3175 , 445 , 547 , 553 , 456 , 517 , 553 , 457 , 553 , 557 , 553 , 57 , 557 , 557 , 553 , 57 , 57 , 557 , 553 , 57 , 57 ,	Fainten (sigar)	Onde Ratio	
Intercognetist Tury, Tur	Execution Eventself	- 0.000001 - 75400 1 - 75400 1	11111111111111111111111111111111111111	### Tubal 1 21 日 第122 日 第12 日	Wingets 有名字》的是在我们之前就是一个不能的一个有的情况。 在名字的现在分词是有些有些的。 在名字的是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是	Datab Harm M. Resolut, 1915, O. 2017 Bill Add, 1965 1917 Bill Add, 1965 1917 Bill Add, 1965 1917 Bill Add, 1917 1917 Bill Add, 1917 1917 Bill Add, 1917 2010 Bill Add, 1917 2017 Bill Add, 1917 1917 Bill Add, 19	Famati (operchante) Famali (control) Onto Neto	D _	Christic Foldonsert II Shafr of Subgroup Charlotte at 1, 2020 Charlotte at 1, 2020 Dang et al., 2020 Fang et al., 2020 Fang et al., 2020 Guara et al., 2020 Guara et al., 2020 Halang et al., 2020 Jang et al., 2020 Jang et al., 2020 Jang et al., 2020 Li(2) et al., 2020 Li et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Tiotal 1 49 27 0 467 124 173 30 3 10 20 14 269 20 14 269 20 56 236 25	tt 11 10 8 8 3 2 1 0 2 8	Total V 147 1 21 1 783 352 828 52 258 51 379 217 92 115 217 92 103 33	9,0% 2,0% 1,5% 21,4% 6,8% 3,3% 1,1% 0,8% 0,8% 0,8% 0,7% 1,7% 10,1% 17,7% 2,7% 4,9% 5,9% 0,9% 2,0%	M.H. Freed, 1954; Ci 7 1.46 (144); A.27 2.06 (147); Ci 84, S.307 2.06 (147); Ci 84, S.307 2.06 (147); Ci 84, S.307 5.47 (2.24, S.30); S.47 (2.24, S.30); Ci 87 (2.47, S.37); Ci 87 (2.47, S.37); Ci 87 (2.47, S.37); Ci 89 (2.47, S.37); Ci 80 (2.47, S.37);Ci 80 (2.47, S.37); Ci 80 (2.47, S.37); Ci 80 (2.47, S.37);Ci 80 (2.47, S.37);Ci 80 (2.47, S.37); Ci 80 (2	Fainten (sigar)	Onde Ratio	
Intercopresents Table Total for sense affects Table for sense affects Table for sense affects Table for a sense affects Consect of a set 2020 Consect of a set 2020 Annual of a set 2020 Annual of a set 2020 Annual Set 2020 Annua	23 7100 P Severation Freedom 111 10 10 10 10 10 10 10 10 1	- 0.000001 - 70404 1 - 70404 1	1000 47 4 2 0 12 10 2 10 3 1 2 4 11 [2 10 5 12 3 9 5 13 11 5 12 8 5	988 Toldar 147 11 2022 2022 2021 2020 2022 2021 2020 2021 20	Window 4.5% 1.2% 8.53% 8.52% 8.53% 8	Data Rate Res. Research, 1910, CJ D 758, B14, Tel D 758, B14, Tel Res. Research, 1910, CJ Res.	Constanting Passada gommag	D _	Christik Politowstry II Stady of Subgetop Christike et al., 3520 Christike et al., 3520 Christike et al., 3520 Dang stal., 2020 Fang et al., 2020 Data et al., 2020 HeiCB et al., 2020 HeiCB et al., 2020 HeiCB et al., 2020 HeiCB et al., 2020 Life et al., 2020 Life et al., 2020 HeicH et al., 2020 HeicH et al., 2020 HeicH et al., 2020 HeicH et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Totar 1 40 27 0 4407 124 173 3 10 20 3 10 209 14 269 105 56 239 20 38 20 38 20 38 20 38 20 38 20 59	tt 11 10 8 8 3 2 1 0 2 8	Total V 147 21 18 352 838 51 52 251 52 25 379 327 115 27 102 82	9,0% 2,0% 1,5% 21,4% 6,8% 3,3% 1,1% 0,8% 0,8% 0,8% 0,7% 1,7% 10,1% 17,7% 2,7% 4,9% 5,9% 0,9% 2,0%	<u>M.H. (1996)</u> , 140 , 144 , 4 , 327 , 140 , 144 , 4 , 327 , 177 , 1206 , 175 , 277 , 4206 , 547 , 172 , 4216 , 547 , 1726 , 437 , 1736 , 437 , 1736 , 437 , 1736 , 437 , 1736 , 439 , 1737 , 1736 , 239 , 1038 , 5377 , 144 , 1532 , 3175 , 442 , 543 , 3175 , 443 , 543 , 3175 , 444 , 543 , 3175 , 445 , 547 , 553 , 456 , 517 , 553 , 457 , 553 , 557 , 553 , 57 , 557 , 557 , 553 , 57 , 57 , 557 , 553 , 57 , 57 ,	Fainten (sigar)	Onde Ratio	
Inter-courselve Tury, Tury, Tury, T	23 7 200 (P Severate Freedor 11 1 1 1 1 1 1 1 1 1 1 1 1	- 0.0000001 - 0.0000001 	11111111111111111111111111111111111111	1000 1010	Wingets 有名字》的是在我们之前就是一个不能的一个有的情况。 在名字的现在分词是有些有些的。 在名字的是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是一个是	Data Rate (a), Review (b), Review (c), Re	Panant (separatement) Panant (separat	D_	Christic Foldonsert II Shafr of Subgroup Charlotte at 1, 2020 Charlotte at 1, 2020 Dang et al., 2020 Fang et al., 2020 Fang et al., 2020 Guara et al., 2020 Guara et al., 2020 Halang et al., 2020 Jang et al., 2020 Jang et al., 2020 Jang et al., 2020 Li(2) et al., 2020 Li et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Tiotal 1 49 27 0 467 124 173 30 3 10 20 14 269 20 14 269 20 56 236 25	tt 11 10 8 8 3 2 1 0 2 8	Total V 147 1 21 1 783 352 828 52 258 51 379 217 92 115 217 92 103 33	9,0% 2,0% 1,5% 21,4% 6,8% 3,3% 1,1% 0,8% 0,8% 0,8% 0,7% 1,7% 10,1% 17,7% 2,7% 4,9% 5,9% 0,9% 2,0%	M.H. Freed, 1954; Ci 7 1.46 (144); A.27 2.06 (147); Ci 84, S.307 2.06 (147); Ci 84, S.307 2.06 (147); Ci 84, S.307 5.47 (2.24, S.30); S.47 (2.24, S.30); Ci 87 (2.47, S.37); Ci 87 (2.47, S.37); Ci 87 (2.47, S.37); Ci 89 (2.47, S.37); Ci 80 (2.47, S.37);Ci 80 (2.47, S.37); Ci 80 (2.47, S.37); Ci 80 (2.47, S.37);Ci 80 (2.47, S.37);Ci 80 (2.47, S.37); Ci 80 (2	Fainten (sigar)	Onde Ratio	
Intercopresents Turk, Total for sensest affect Banady or Interpresent Connector (al., 2020) Connector (al., 2020) Connector (al., 2020) Connector (al., 2020) Connector (al., 2020) Connector (al., 2020) Farga affa, 2020 Nexture (al., 2020) Nexture (a	2.5 7 100 Φ Invested Tents 1 1 1 1 1 1 1 1 1 1 1 1 1	- 0.000001 - 70404 1 - 70404 1	1000 47 4 2 0 12 10 2 10 3 1 2 4 11 [2 10 5 12 3 9 5 13 11 5 12 8 5	1000 1010	Weight / 45% 13% 25% 15% 15% 15% 15% 15% 15% 15% 1	Datab Rate: 66, Resolve, 101: C. 1976; B. 47, 106 1976; B. 47, 106 1976; B. 47, 106 1987; B. 49, 100 1987; B. 49, 100 1987; B. 49, 100 1987; B. 49, 100 1987; B. 40, 100 1997; B. 40,	Panant (separatement) Panant (separat	D _	Christic Polisionari II Shafa of Subgroup Charlot of Subgroup Denging et al., 2020 Dang et al., 2020 Fang et al., 2020 Fang et al., 2020 Guara et al., 2020 Halang et al., 2020 Anaron et al., 2020 Anaron et al., 2020 Jung et al., 2020 Jung et al., 2020 Dist et al., 2020 Misca et al., 2020 Weaging et al., 2020 Dist et al., 2020 Dist et al., 2020 Weaging et al., 2020 Zhang et al., 2020 Dist et al., 2020 Dist et al., 2020 Dist et al., 2020 Dist et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Total 1 Total 1 40 407 124 173 30 31 8 20 144 269 200 144 269 206 206 206 206 206 206 206 206	tt 11 10 8 8 3 2 1 0 2 8	Total V 147 1 18 352 828 51 52 379 258 51 115 27 102 83 82 83	9,0% 2,0% 1,5% 21,4% 6,8% 3,3% 1,1% 0,8% 0,8% 0,8% 0,7% 1,7% 2,7% 4,9% 5,9% 0,9% 0,7% 1,1%	<u>M.H. Freed. 1954</u> (1) 1.46 (Ja 44, 4, 27) 1.97 (Ja 16, 1307) 1.06 (Ja 7, 420, 1307) 1.06 (Ja 7, 420, 15, 27) 5.47 (Ja 24, 1307) 5.47 (Ja 24, 1307) 1.02 (Ja 17, 420, 147) 1.02 (Ja 17, 420, 147) 1.02 (Ja 17, 420, 147) 1.02 (Ja 17, 17) 1.02 (Ja 17, 12) 1.02 (Ja 17, 12) 1	Fainten (sigar)	Onde Ratio	
Intercopresent Tury, Tur	23 7 100 P Investments Freedox 1 11 1 0 3 13 1 17 1 17 3 13 1 17 3 14 1 17 1 1	- 0.000001 - 0.000001 	1000 47 4 2 0 12 10 2 10 3 1 2 4 11 [2 10 5 12 3 9 5 13 11 5 12 8 5	10000000000000000000000000000000000000	Winght 	Datas term (m. Rev. 1, m. C.) (m. Rev. 1, m. C.	Panant (separatement) Panant (separat	D.	Chrinali Feldenmerri D Staty of Subjecture Christian et al., 2020 Christian et al., 2020 Christian et al., 2020 Faring et al., 2020 Faring et al., 2020 Name et al., 2020 Americal, 2020 Heating et al., 2020 Americal, 2020 Heating et al., 2020 Heating et al., 2020 Li2(2) et al., 2020 Li2(2) et al., 2020 Li2(2) et al., 2020 Vision et al., 2020 Transpill et al., 2020 Dranspill et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Total 1 Total 1 40 407 124 123 3 1 20 14 269 105 56 126 105 56 126 105 56 126 105 56 126 105 105 10 10 10 10 10 10 10 10 10 10	Events 11 1 10 8 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 10 2 10 2 8 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 10 2 10 10 2 10 10 10 10 10 10 10 10 10 10	Tentor V 147 21 8 783 352 828 828 52 379 227 92 115 127 102 83 82 83 82 93 82 93 82 93 83	9,0% 2,0% 1,5% 21,7% 6,8% 3,3% 1,1% 0,8% 0,2% 1,1% 0,2% 1,7% 4,9% 5,9% 0,9% 3,0% 0,7% 1,1% 2,5%	<u>Multi, Reset, 1956</u> , ct. 1.461 [2446, 43, 27, 1.471 [2146, 13, 377] 2.06 [215, 227 45] 5.47 [2146, 13, 377] 2.06 [215, 227 45] 5.47 [214, 1330] 4.07 [214, 2130] 4.07 [214, 2130] 2.05 [2016, 25, 77] 2.05 [216, 21, 71, 216] 2.05 [216, 21, 71, 216] 2.05 [216, 21, 71, 216] 2.05 [216, 21, 71, 216] 2.05 [217, 513] 3.05 [217, 513] 3.05 [213, 2145] 2.15 [216, 213, 71, 216] 2.15 [216, 213, 71, 7	Fainten (sigar)	Onde Ratio	
Intercopretative Table 2014 Table to ensure at the table 2014 Table to ensure at table 2014 Table to ensure at table 2014 Character at a 2012 Character	23 7 100 P Investments Freedox 1 11 1 0 3 13 1 17 1 17 3 13 1 17 3 14 1 17 1 1	- 0.0000001 - 0.0000001 	1000 01 4 2 0 12 10 2 10 3 1 2 4 11 [2 10 5 12 3 5 5 5 11 1 5 12 8 5	147 147 117 117 117 117 117 117 117 117	Winstein 	Data Rate: Res. Research, 1910, CJ 1740, Bit 1740, CJ 1740, Bit	Panant (separatement) Panant (separat	D.	Christic Polisionari II Shafa of Subgroup Charlot of Subgroup Denging et al., 2020 Dang et al., 2020 Fang et al., 2020 Fang et al., 2020 Guara et al., 2020 Halang et al., 2020 Anaron et al., 2020 Anaron et al., 2020 Jung et al., 2020 Jung et al., 2020 Dist et al., 2020 Misca et al., 2020 Weaging et al., 2020 Dist et al., 2020 Dist et al., 2020 Weaging et al., 2020 Zhang et al., 2020 Dist et al., 2020 Dist et al., 2020 Dist et al., 2020 Dist et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Total 1 Total 1 40 407 124 173 30 31 8 20 144 269 200 144 269 206 206 206 206 206 206 206 206	Events 11 1 10 8 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 10 2 10 2 8 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 10 2 10 10 2 10 10 10 10 10 10 10 10 10 10	Total V 147 1 18 352 828 51 52 379 258 51 115 27 102 83 82 83	9,0% 2,0% 1,5% 21,4% 6,8% 3,3% 1,1% 0,8% 0,8% 0,8% 0,7% 1,7% 2,7% 4,9% 5,9% 0,9% 0,7% 1,1%	<u>M.H. Freed.</u> 1994 (1) 1.46 (1) 44 (4, 27) 1.07 (1) 80, (3) 07 1.06 (1) 15, 27 45 5.47 (2) 24, (3) 07 5.47 (2) 24, (3) 07 5.47 (2) 24, (3) 07 5.47 (2) 24, (3) 07 2.10 (1) 17, 20 2.10 (1) 17, 17 00 2.10 (1) 17, 10 (1) 3.10 (1) 17, 10 (1) 17, 10 (1) 3.10 (1) 17, 10 (1) 17, 10 (1) 3.10 (1) 17, 10 (1) 17, 10 (1) 17, 10 (1) 3.10 (1) 17, 10 (1) 17,	Fainten (sigar)	Onde Ratio	
Intercopresents Tany, Total for several determinants of the several determinants of	23 7 100 P Investments Freedox 1 11 1 0 3 13 1 17 1 17 3 13 1 17 3 14 1 17 1 1	- 0.0000001 - 700001 - 7000001 - 7000001 - 7000001 - 70000001 - 70000001 - 7000000 - 7000000 - 7000000 - 7000000 - 7000000 - 7000000 - 70000000 - 7000000 - 70000000 - 70000000 - 70000000 - 70000000 - 70000000 - 70000000 - 70000000 - 700000000 - 70000000000000 - 700000000000000 - 7000000000000000000000000000000000000	1000 01 4 2 10 12 (3 2 10 7 - 2 4 3 17 10 7 12 2 8 9 5 12 1 - 8 12 8 5 2 5 5 5	10000000000000000000000000000000000000	Winnets 42198 2219 2219	Data Rate 4.4. Area of the second se	Panant (separatement) Panant (separat	D.	Chrinali Feldenmerri D Stady of Subjection Christian et al., 2020 Christian et al., 2020 Christian et al., 2020 Faring et al., 2020 Faring et al., 2020 Sering et al., 2020 Januard et al., 2020 Januard et al., 2020 Januard et al., 2020 Januard et al., 2020 Licit et al., 2020 Licit et al., 2020 Vision et al., 2020 Vision et al., 2020 Dissippid et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Total (Total (40) 407 0 407 124 124 123 3 0 124 200 14 205 10 20 14 205 3 10 20 14 20 20 3 124 155 20 20 3 124 155 20 20 155 20 20 155 20 20 155 20 20 20 20 20 20 20 20 20 20	Events 11 1 10 8 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 10 2 10 2 8 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 10 2 10 10 2 10 10 10 10 10 10 10 10 10 10	Statut V 147 21 8 783 352 828 51 52 52 258 51 52 379 227 115 27 102 83 131 111	9,0% 2,0% 1,0% 2,1 #% 0,0% 0,7% 1,1% 0,0% 0,7% 1,1% 2,7% 4,9% 5,9% 0,7% 1,1% 2,5% 1,0%	<u>Mult</u> , Reset, 1996. 1 1.461 [3.46], 4.327, 1.471 [3.16, 13.077 2.06 [0.15, 227-43] 5.47 [2.24, 13.077 5.47 [2.24, 13.077 5.47 [2.24, 13.07] 5.47 [2.24, 13.07] 5.48 [2.24, 13.07] 5.48 [2.24, 13.07] 5.47 [2.24, 13.07]	Fainten (sigar)	Onde Ratio	
Intercopresents Tany, Total for several determinants of the several determinants of	23 7 100 P Investments Freedox 1 11 1 0 3 13 1 17 1 17 3 13 1 17 3 14 1 17 1 1	- 0.0000001 - 0.0000001 	1000 01 4 2 0 12 10 2 10 3 1 2 4 11 [2 10 5 12 3 5 5 5 11 1 5 12 8 5	147 147 117 117 117 117 117 117 117 117	Winstein 	Data Rate: Res. Research, 1910, CJ 1740, Bit 1740, CJ 1740, Bit	Panant (separatement) Panant (separat	D_	Christic Polisionary II Shoth of Subgroups Charlot et al., 2020 Charlot et al., 2020 Fang et al., 2020 Fang et al., 2020 Fang et al., 2020 Fang et al., 2020 Guara et al., 2020 Huang et al., 2020 Anaret et al., 2020 Anaret et al., 2020 Anaret et al., 2020 Dave et al., 2020 Ence at al. 2020 Ence at al., 2020 Ence at al	1. Sevenald books 5 5 1 2 0 1 4 1 2 0 0 3 2 16 11 1 4 1 3 0 2 1 1 2 2 1 2 2 2 1 2 2 2 2 1 2 2 2 2	Total 1 Total 1 40 407 124 123 3 1 20 14 269 105 56 126 105 56 126 105 56 126 105 56 126 105 105 10 10 10 10 10 10 10 10 10 10	Events 11 1 10 8 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 10 2 10 2 8 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 10 2 10 10 2 10 10 10 10 10 10 10 10 10 10	Tentor V 147 21 8 783 352 828 828 52 379 227 92 115 127 102 83 82 83 82 93 82 93 82 93 83	9,0% 2,0% 1,0% 2,1 #% 0,0% 0,7% 1,1% 0,0% 0,7% 1,1% 2,7% 4,9% 5,9% 0,7% 1,1% 2,5% 1,0%	<u>Multi, Reset, 1956</u> , ct. 1.461 [2446, 4327, 1.471 [2346, 1307] 2.06 [171, 2016, 1307] 2.06 [171, 2016, 1307] 2.06 [171, 4030 5.47 [234, 1330] 4.07 [244, 1314] 4.07 [244, 1314] 4.07 [244, 1314] 2.07 [2016, 2517] 2.08 [141, 171, 1130] 2.08 [141, 171, 1130] 2.09 [241, 1234] 2.09 [241, 1234] 2.00 [241, 12	Fainten (sigar)	Onde Ratio	
Intercopresents Tuck- Total Tuc seesal affect Stade or leading total Characteristic and a state Characteristic and a state Characteristic and a state Characteristic and a state State or leading total Fang et al. 2020 Devent of et al. 2020 Dev	23 7 100 P Investments Freedox 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1	- 0.0000001 - 700001 - 7000001 - 7000001 - 7000001 - 70000001 - 70000001 - 7000000 - 7000000 - 7000000 - 7000000 - 7000000 - 7000000 - 70000000 - 7000000 - 70000000 - 70000000 - 70000000 - 70000000 - 70000000 - 70000000 - 70000000 - 700000000 - 70000000000000 - 700000000000000 - 7000000000000000000000000000000000000	1000 01 4 2 10 12 (3 2 10 7 - 2 4 3 17 10 7 12 2 8 9 5 12 1 - 8 12 8 5 2 5 5 5	998 1471 802 3429 802 3429 802 2529 82 2529	Winnets 42198 2219 2219	Deales Rese: 66. Association, 1010, CD 1. Phys. Res. 7, 9720 1. P	Panant (separatement) Panant (separat	D_	Chrinali Feldenmerri D Stady of Subjection Christian et al., 2020 Christian et al., 2020 Christian et al., 2020 Faring et al., 2020 Faring et al., 2020 Sering et al., 2020 Januard et al., 2020 Januard et al., 2020 Januard et al., 2020 Januard et al., 2020 Licit et al., 2020 Licit et al., 2020 Vision et al., 2020 Vision et al., 2020 Dissippid et al., 2020	5 Seventa Eventa 1 2 70 14 8 2 0 0 0 3 7 16	Total (Total (40) 407 0 407 124 124 123 3 0 124 200 14 205 10 20 14 205 3 10 20 14 20 20 3 124 155 20 20 3 124 155 20 20 155 20 20 155 20 20 155 20 20 20 20 20 20 20 20 20 20	Events 11 1 10 8 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 7 2 10 2 8 10 2 10 2 8 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 2 10 10 2 10 10 2 10 10 10 10 10 10 10 10 10 10	Statut V 147 21 187 352 808 51 528 51 527 379 215 377 102 83 115 37 103 83 111 111	9,0% 2,0% 1,0% 2,1 #% 0,0% 0,7% 1,1% 0,0% 0,7% 1,1% 2,7% 4,9% 5,9% 0,7% 1,1% 2,5% 1,0%	<u>Mult</u> , Reset, 1996. 1 1.461 [3.46], 4.327, 1.471 [3.16, 13.077 2.06 [0.15, 227-43] 5.47 [2.24, 13.077 5.47 [2.24, 13.077 5.47 [2.24, 13.07] 5.47 [2.24, 13.07] 5.48 [2.24, 13.07] 5.48 [2.24, 13.07] 5.47 [2.24, 13.07]	Fainten (sigar)	Onde Ratio	
Intercopresents Turk, Table Services and the Status of a sense and the Status of a sense and Connects of a set , 2020 Connects of a set , 2020 Connects of a set , 2020 Connects of a set , 2020 Connect of a set	Severation (P) Severation Freedom 1 (P) 1 (P)	2.00001) 730801 11 407 年初12174日 11 年初12174日 11 年初214日 11 年初214日 11 日 11 日 11 日 11 日 11 日 11 日 11 日 1	11 1 2 0 12 0 2 0 3 1 3 4 1 1 1 0 5 1 2 3 3 5 1 1 1 5 1 2 8 5 1 1 1 5 1 3 5 1 1 5 1 1 5 1 1 5 1 5 1	998 1421 1421 1421 1422 1	9900011 44% 421% 44% 42% 42% 42% 42% 42% 42% 42% 42% 42	Data Rate 4.4. Area of the second se	Panant (separatement) Panant (separat	D _	Chrinicki Policinemerty ID Starty of Subgroups Chernity et al., 2020 Chernity et al., 2020 Drang et al., 2020 Faring et al., 2020 Faring et al., 2020 Chernity and L., 2020 Huang et al., 2020 Americal, 2020 Americal, 2020 Americal, 2020 Americal, 2020 Licit et al., 2020 Dise et al., 2020	5 Sevents/C 5 1 2 D 7 D 14 8 2 0 0 0 3 7 16 11 1 2 0 0 2 1 2 2 2 5 3 7 6 5 1 2 2 D 7 D 14 8 2 0 0 0 3 7 16 17 2 D 7 D 7 D 7 D 7 D 7 D 7 D 7 D 7	Hical 1 104at 4 40 7 9 4 417 9 4124 177 9 3 10 20 1134 209 1155 209 116 209 117 200 118 209 118 2	tt 1 10 8 8 7 7 10 8 8 7 7 10 7 8 8 7 7 10 7 8 8 7 7 10 7 8 8 7 7 7 10 8 8 7 7 7 10 8 8 8 7 7 7 10 8 8 8 7 7 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10	Teledy V 147 147 187 152 1983 152 1983 152 1983 152 1979 258 1979 155 1979 162 1979 162 1971 162 1973 171 1973 173 1974 173 1974 173 1974 174	9,0% 2,0% 1,0% 2,1 #% 0,0% 0,7% 1,1% 0,0% 0,7% 1,1% 2,7% 4,9% 5,9% 0,7% 1,1% 2,5% 1,0%	<u>M.H. Freed. 1954</u> (1) 1.46 (1) 44, 427 1.07 (1) 48, 43, 427 2.06 (1) 45, 27 45 5.47 (2) 44, 1307 2.06 (1) 45, 27 45 5.47 (2) 44, 1307 2.05 (1) 47, 425 5.47 (2) 44, 1307 2.05 (1) 47, 37 95 2.05 (1) 47, 37 95 2.05 (1) 47, 23 45 2.05 (1) 47, 23 45 2.07 (1) 47, 23 41 2.07 (1) 72, 3, 111 2.07 (1) 72, 3, 111 3.07 (1) 72, 3, 1		Onde Ratio	-
Intercopresents Table 2014 Table to research when the table of the table of the table of tab	Exercise Freedom Freedom 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2.00001) 70401 1 40 40 40 40 40 40 40 40 40 41 41 41 41 41 41 41 41 41 41 41 41 41	er a 200 222 20 2 4 2 20 2 20 2 4 2 2 20 2 2 2 2	998 1421 8 1421 8 1421 8 1422 8 1423 8 1433 8 1	9900011 44% 421% 44% 42% 42% 42% 42% 42% 42% 42% 42% 42	Deales Rese: 66. Association, 1010, CD 1. Phys. Res. 7, 9720 1. P	Panant (separatement) Panant (separat	D_	Christic Polisionary II Shoth of Subgroups Charlot et al., 2020 Charlot et al., 2020 Fang et al., 2020 Fang et al., 2020 Fang et al., 2020 Fang et al., 2020 Guara et al., 2020 Huang et al., 2020 Anaret et al., 2020 Anaret et al., 2020 Anaret et al., 2020 Dave et al., 2020 Ence at al. 2020 Ence at al., 2020 Ence at al	1. Semandici Booms 5 5 5 1 2 2 0 1 4 5 2 0 0 3 2 16 11 1 4 1 3 2 0 0 3 2 16 11 2 0 0 3 2 16 11 2 2 0 0 3 2 2 0 0 3 2 2 0 0 3 2 2 0 0 3 2 2 0 0 3 2 2 0 0 5 5 5 1 2 0 0 3 2 0 0 5 5 1 2 0 0 5 5 5 1 2 0 0 5 5 1 2 0 0 5 5 5 1 2 0 0 5 5 1 2 0 0 5 5 5 1 2 0 0 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Histoit Total I I 400 27 0 497 407 0 124 121 1124 1123 3 3 0 140 124 125 50 3 124 100 14 125 50 3 124 125 101 105 52.56 30 36 16 <td>tt 1 10 8 8 7 7 10 8 8 7 7 10 7 8 8 7 7 10 7 8 8 7 7 10 7 8 8 7 7 7 10 8 8 7 7 7 10 8 8 8 7 7 7 10 8 8 8 7 7 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10</td> <td>Teledy V 147 147 187 152 1983 152 1983 152 1983 152 1979 258 1979 155 1979 162 1979 162 1971 162 1973 171 1973 173 1974 173 1974 173 1974 174</td> <td>9,0% 2,0% 1,0% 2,1 #% 0,0% 0,7% 1,1% 0,0% 0,7% 1,1% 2,7% 4,9% 5,9% 0,7% 1,1% 2,5% 1,0%</td> <td><u>M.H. Freed. 1954</u> (1) 1.46 (1) 44, 427 1.07 (1) 48, 43, 427 2.06 (1) 45, 27 45 5.47 (2) 44, 1307 2.06 (1) 45, 27 45 5.47 (2) 44, 1307 2.05 (1) 47, 425 5.47 (2) 44, 1307 2.05 (1) 47, 37 95 2.05 (1) 47, 37 95 2.05 (1) 47, 23 45 2.05 (1) 47, 23 45 2.07 (1) 47, 23 41 2.07 (1) 72, 3, 111 2.07 (1) 72, 3, 111 3.07 (1) 72, 3, 1</td> <td></td> <td>Onde Ratio</td> <td></td>	tt 1 10 8 8 7 7 10 8 8 7 7 10 7 8 8 7 7 10 7 8 8 7 7 10 7 8 8 7 7 7 10 8 8 7 7 7 10 8 8 8 7 7 7 10 8 8 8 7 7 10 9 10 10 10 10 10 10 10 10 10 10 10 10 10	Teledy V 147 147 187 152 1983 152 1983 152 1983 152 1979 258 1979 155 1979 162 1979 162 1971 162 1973 171 1973 173 1974 173 1974 173 1974 174	9,0% 2,0% 1,0% 2,1 #% 0,0% 0,7% 1,1% 0,0% 0,7% 1,1% 2,7% 4,9% 5,9% 0,7% 1,1% 2,5% 1,0%	<u>M.H. Freed. 1954</u> (1) 1.46 (1) 44, 427 1.07 (1) 48, 43, 427 2.06 (1) 45, 27 45 5.47 (2) 44, 1307 2.06 (1) 45, 27 45 5.47 (2) 44, 1307 2.05 (1) 47, 425 5.47 (2) 44, 1307 2.05 (1) 47, 37 95 2.05 (1) 47, 37 95 2.05 (1) 47, 23 45 2.05 (1) 47, 23 45 2.07 (1) 47, 23 41 2.07 (1) 72, 3, 111 2.07 (1) 72, 3, 111 3.07 (1) 72, 3, 1		Onde Ratio	

Figure 2 - The Floret plots of comorbidities associated with severe COVID-19.

(A) Floret plot of association between Hypertension and the risk of severe COVID-19. (B) Floret plot of association between Diabetes and the risk of severe COVID-19. (C) Floret plot of association between Cardiovascular disease and the risk of severe COVID-19. (D) Floret plot of association between Chronic pulmonary disease and the risk of severe COVID-19. Source: author of this research (2020).

3.2.3. Cardiovascular disease

Thirty-two studies were included in the meta-analysis to assess susceptibility to severe COVID-19 in individuals with cardiovascular disease. Overall, these studies analysed 2,452 severe and 6,461 non-severe COVID-19 patients. The pooled ORs showed that patients with cardiovascular disease were 2.36-fold increased risk to developing the severe form of COVID-19 (OR = 2.36 [95% CI = 1.98 - 2.80], P < 0.00001) (Table 2). The forest plot for this association is shown in Figure 2C. In this analysis, publication bias (Egger test: Z = 3.3947, P = 0.0007) was detected, but heterogeneity (χ 2 = 41.93, P = 0.09, I2 = 26%) was not found (Table 2).

Sixteen studies with 39,637 hospitalized COVID-19 patients who died and 295,421 hospitalized COVID-19 patients who recovered were included in the meta-analysis to assess the risk of death in individuals with cardiovascular disease. The pooled ORs showed that patients hospitalized for COVID-19 with cardiovascular disease had a 2.91-fold increased risk of dying (OR = 2.91 [95% CI = 2.26 - 3.73], P < 0.00001) (Table 2). The forest plot of this association is shown in Figure 4A. Publication bias (Egger test: Z = 10.4782, P < 0.0001) and heterogeneity (χ 2 = 30.39, P = 0.01, I2 = 51%) were demonstrated in this analysis (Table 2).

3.2.4. Chronic pulmonary disease

Twenty-two studies were included in the meta-analysis to assess susceptibility to severe COVID-19 in individuals with chronic pulmonary disease. The total sample was composed by 1,816 severe and 3,992 non-severe COVID-19 patients.

The pooled ORs showed that patients with chronic pulmonary disease had a 2.31-fold increased risk of developing the severe form of COVID-19 (OR = 2.31 [95% CI = 1.72 - 3.11], P < 0.00001) (Table 2). The forest plot of this association is shown in Figure 2D. Publication bias (Egger test: Z = 0.8841, P = 0.3766) and heterogeneity (χ 2 = 19.18, P = 0.57, I2 = 0%) were not observed in this analysis (Table 2).

Fifteen studies comprising 39,583 hospitalized COVID-19 patients who died 295,344 hospitalized COVID-19 patients who recovered were included in the meta-analysis to assess the risk of death in individuals with chronic pulmonary disease. The pooled ORs showed that COVID-19 patients with chronic pulmonary disease were associated with a 1.97-fold increased risk of dying (OR = 1.97 [95% CI = 1.43 - 2.72], P < 0.0001) during hospitalization (Table 2). The forest plot of this association is shown in Figure 4B. Publication bias (Egger test: Z = 13.3344, P < 0.0001) and heterogeneity (χ 2 = 23.19, P = 0.04, I2 = 44%) (Table 2) were detected.




Figure 3 - The Floret plots of comorbidities associated with severity and mortality by COVID-19.

(A) Floret plot of association between Chronic kidney disease and the risk of severe COVID-19. (B) Floret plot of association between Cerebrovascular disease and the risk of severe COVID-19. (C) Floret plot of association between Hypertension and the risk of COVID-19 death. (D) Floret plot of association between Diabetes and the risk of COVID-19 death. Source: author of this research (2020).

3.2.5. Chronic kidney disease

Seventeen studies containing 1,527 severe and 3,928 non-severe COVID-19 patients were included in the metaanalysis to assess susceptibility to severe form of the disease in individuals with chronic kidney disease. The pooled ORs showed that patients with chronic kidney disease had a 2.55-fold increased risk of developing severe COVID-19 (OR = 2.55 [95% CI = 1.11 - 5.84], P = 0.03) (Table 2). The forest plot of this association is shown in Figure 3A. No publication of bias (Egger test: Z = 0.6908, P = 0.4897) was found, but heterogeneity ($\chi 2 = 52.45$, P < 0.00001, I2 = 69%) was observed in this analysis (Table 2).

Twelve studies comprising 39,443 hospitalized COVID-19 patients who died and 295,129 hospitalized COVID-19 patients who recovered were included in the meta-analysis to assess the risk of death in individuals with chronic kidney disease. The pooled ORs showed that hospitalized COVID-19 patients with chronic kidney disease had a 3.01- fold increased

risk of dying (OR = 3.01 [95% CI = 1.94 - 4.66], P < 0.00001) (Table 2). The forest plot of this association is shown in Figure 4C. Publication of bias (Egger test: Z = 13.0460, P < 0.0001) and heterogeneity (χ 2 = 20.05, P = 0.04, I2 = 45%) were detected in this analysis (Table 2).




Figure 4 - The Floret plots of comorbidities associated with COVID-19 mortality.

(A) Floret plot of association between Cardiovascular disease and the risk of COVID-19 death. (B) Floret plot of association between Chronic pulmonary disease and the risk of COVID-19 death. (C) Floret plot of association between Chronic kidney disease and the risk of COVID-19 death. (D) Floret plot of association between Cerebrovascular disease and the risk of COVID-19 death. (E) Floret plot of association between Malignancy and the risk of COVID-19 death. Source: author of this research (2020).

3.2.6. Cerebrovascular disease

Thirteen studies were included in the meta-analysis to assess susceptibility to severe COVID-19 in individuals with cerebrovascular disease. The sample was composed of 1,195 severe and 3,088 non-severe COVID-19 patients. The pooled ORs showed that patients with cerebrovascular disease were associated with a 2.51-fold increased risk of developing the severe COVID-19 (OR = 2.51 [95% CI = 1.68 - 3.76], P < 0.00001) (Table 2). The forest plot of this association is shown in Figure 3B. Publication of bias (Egger test: Z = 0.1614, P = 0.8718) and heterogeneity (χ 2 = 10.76, P = 0.55, I2 = 0%) were not found in this analysis (Table 2).

Seven studies containing 809 hospitalized COVID-19 patients who died and 1,746 hospitalized COVID-19 patients who recovered were included in the meta-analysis to assess the risk of death in individuals with cerebrovascular disease. The pooled ORs showed that hospitalized COVID-19 patients with cerebrovascular disease had a 2.40-fold increased risk of death (OR = 2.40 [95% CI = 1.60 - 3.60], P < 0.0001) (Table 2). The forest plot of this association is shown in Figure 4D. Publication bias (Egger test: Z = 0.6710, P = 0.5022) and heterogeneity ($\chi 2 = 11.15$, P = 0.08, I2 = 46%) were not observed in this analysis (Table 2).

3.2.7. Chronic liver disease

Sixteen studies were included in the meta-analysis to assess susceptibility to severe COVID-19 in individuals with the chronic liver disease. These studies analysed 1,364 severe and 3,380 non-severe COVID-19 patients. There was no significant association between patients with the chronic liver disease and severe form of COVID-19 (OR = 0.99 [95% CI = 0.64 - 1.52], P = 0.95) (Table 2). Publication of bias (Egger test: Z = 0.3035, P = 0.7615) and heterogeneity ($\chi 2 = 13.28$, P = 0.58, I2 = 0%) were not observed in this analysis (Table 2).

Five studies containing 240 hospitalized COVID-19 patients who died and 660 hospitalized COVID-19 patients who recovered were included in the meta-analysis to assess the risk of death in individuals with chronic liver disease. There was no significant association between patients with chronic liver disease and the risk of death for COVID-19 (OR = 1.72 [95% CI = 0.87 - 3.39], P = 0.14) (Table 2). Publication of bias (Egger test: Z = 0.3098, P = 0.7567) and heterogeneity (χ 2 = 3.02, P = 0.55, I2 = 0%) were not detected in this analysis (Table 2).

3.2.8. Malignancy

Twenty studies with 1,787 severe and 3,781 non-severe COVID-19 patients were included in the meta-analysis to assess susceptibility to severe COVID-19 in individuals with some type of cancer. No association was found between malignancy and severe form of COVID-19 (OR = 1.40 [95% CI = 1.00 - 1.96], P = 0.05) (Table 2). Publication of bias (Egger test: Z = 0.1432, P = 0.8861) and heterogeneity ($\chi 2 = 23.51$, P = 0.22, I2 = 19%) were not detected in this analysis (Table 2).

Twelve studies containing 1,134 hospitalized COVID-19 patients who died and 1,733 hospitalized COVID-19 patients who recovered were included in the meta-analysis to assess the risk of death in individuals with malignancy. The pooled ORs showed that COVID-19 patients with malignancy had a 1.81-fold increased risk of death (OR = 1.81 [95% CI = 1.30 - 2.52], P = 0.0004) during hospitalization (Table 2). The forest plot of this association is shown in Figure 4E. Publication of bias (Egger test: Z = 0.6944, P = 0.4874) and heterogeneity (χ 2 = 11.29, P = 0.42, I2 = 3%) were not found in the analysis (Table 2). (TNR font 10 – justified – space 1,5).

4. Discussion

Currently, COVID-19 is the most important public health problem in the world, due to its capacity for global expansion. A major challenge for health authorities is to discover the main factors involved in the development of the severe form of the disease and risk of death. Studies have demonstrated a high prevalence of comorbidities in COVID-19 patients who progressed to the severe form of the disease and/or died. We investigated the impact of comorbidities in the susceptibility to severe COVID-19 and the risk of death through a systematic review with meta-analysis.

In our meta-analysis, patients with COVID-19 and with pre-existing cardiovascular disease were about 2-fold more likely to develop severe disease, and among hospitalized COVID-19 patients the risk of death was approximately 3-fold higher in cardiopathy patients when compared to patients without cardiovascular disease. Six recent meta-analyses have shown that COVID-19 patients with cardiovascular disease have approximately a 3- to 4-fold increased risk from developing severe COVID-19 (Aggarwal et al., 2020; Jain & Yuan, 2020; Liu et al., 2020c; Wang et al., 2020d; Wang et al., 2020e; Yang et al., 2020a). At the same time, the meta-analyses carried out by Tian et al. (2020) and Li et al. (2020) showed that patients with this comorbidity had a risk of death 3.80 and 4.85-fold higher in SARS-CoV-2 infection, respectively (Li et al., 2020e; Tian et al., 2020b). Thus, patients with pre-existing cardiovascular diseases infected with SARS-CoV-2 should be monitored more carefully by healthcare professionals, especially cardiologists, to obtain better clinical management.

Hypertension has been considered an important risk factor for severe COVID-19 and disease fatality (Deng et al., 2020; Zhu et al., 2020). In our meta-analysis, hypertensive patients infected with SARS-COV-2 were about 2-fold more likely to develop severe COVID-19 and/or death from this illness. Six previous meta-analysis revealed an association between

hypertensive patients and an increased risk of developing severe COVID-19, with an estimated risk of about 2- to 3-fold higher compared to non-hypertensive patients (Jain & Yuan, 2020; Liu et al., 2020c; Wang et al., 2020d; Wang et al., 2020e; Yang et al., 2020a; Zhang et al., 2020d). Additionally, three recent meta-analyses showed that hypertensive patients with COVID-19 also had a 2- to 3-fold increased risk of dying (Li et al., 2020e; Tian et al., 2020b; Zheng et al., 2020c).

Studies have reported diabetes as a risk factor for worse clinical outcome in patients with COVID-19 (Wang et al., 2020e; Wu et al., 2020b). Our meta-analysis showed that diabetic patients had nearly a 2-fold increased risk of developing the severe form and/or die of COVID-19. Corroborating with our finding, four previous meta-analyses identified that diabetic patients had about a 2.5-fold increased risk of developing the severe form of the disease (Liu et al., 2020c; Wang et al., 2020d; Wang et al., 2020e; Wu et al., 2020b). On the other hand, two meta-analyses found no association between diabetes and severe COVID-19 (Jain & Yuan, 2020; Yang et al., 2020a). Regarding the risk of mortality, similar results were observed in the meta-analyses conducted by Wu et al. (2020) and Tian et al. (2020), in which diabetic patients were associated with a 3- and 2-fold higher risk of mortality from COVID-19, respectively (Tian et al., 2020b; Wu et al., 2020b). In addition, a meta-analysis carried out by Zheng et al. (2020) revealed that diabetes was associated with a 3.68-fold higher risk of developing the critical form of COVID-19 or death from the disease (Zheng et al., 2020c). According to Yang et al. (2006), during the SARS infection, fasting plasma glucose levels were negatively associated with arterial oxygenation (SaO2) and this condition was correlated with mortality and hypoxia (Yang et al., 2006d). Thus, diabetic patients are more susceptible to COVID-19, but this effect has not been fully elucidated yet.

Recent studies have reported that patients with pre-existing chronic pulmonary disease have a high risk of complications and worsening lung injury during the pathogenesis of COVID-19 (Daccord et al., 2020; Taghavi-Farahabadi et al., 2020). The clinical characteristics of COVID-19 demonstrated by some studies revealed that the majority of patients with pre-existing chronic pulmonary disease presented respiratory failure and require ICU intervention. Therefore, these patients appear to be the most susceptible to the development of severe COVID-19. We assessed the risk of severity and mortality in patients with chronic pulmonary disease, which included COPD and asthma. We observed that patients with chronic pulmonary disease had nearly a 2-fold increased risk of developing severe form and/or die of COVID-19. A previous meta-analysis revealed that patients with the chronic pulmonary disease also had nearly a 4-fold higher risk of developing the severe form of COVID-19 (Liu et al., 2020c). In addition, two recent meta-analyses showed that COPD patients had approximately a 6-fold increased risk of death from COVID-19 (Jain & Yuan, 2020; Wang et al., 2020d). Regarding the risk of death, Zhao et al. (2020) found that the risk of death from COVID-19 was almost 2-fold higher in patients with COPD (Zhao et al., 2020), similar result to our findings. However, this association was not observed in the meta-analysis by Tian et al. (2020) (Tian et al., 2020b).

Despite a few previous reports, chronic kidney disease has been associated with the severe form of COVID-19 (Adapa et al., 2020). We showed that patients with chronic kidney disease had a 2.55-fold increased risk to develop severe COVID-19. While, hospitalized COVID-19 patients with chronic kidney disease had a 3-fold increased risk of death when compared to patients without chronic kidney disease. Corroborating with our results, Wang et al. (2020) identified that patients with chronic kidney disease were associated with a 2.22-fold increased risk of developing severe COVID-19 (Wang et al., 2020e). Additionally, the meta-analysis conducted by Tian et al. (2020) revealed that patients with chronic kidney disease had a 9.40-fold higher risk of death from COVID-19 (Tian et al., 2020b). In contrast, a previous meta-analysis found no association between chronic kidney disease and severe COVID-19, but the small number of studies (4 studies) and patients (n = 15) included may have influenced this analysis (Wang et al., 2020d). Several mechanisms can be responsible for the susceptibility of patients with chronic kidney diseases to SARS-CoV-2 infection. First, ACE2 is highly expressed in renal tubular cells, and thus SARS-CoV-2 may directly affect this organ (Fan et al., 2020). Second, that studies have detected kidney injuries in

COVID-19 patients (Li et al., 2020f). Third, chronic kidney disease leads to a series of complications, such as high blood pressure, anemia, water retention and these complications may have a greater effect on SARS-CoV-2 infection (Babitt & Lin, 2012; Drawz et al., 2016). Fourth, chronic kidney disease has been linked to uncontrolled chronic inflammation that can affect the immune response during SARS-CoV-2 infection (Imig & Ryan, 2013; Raj et al., 2015).

Previous reports have suggested that cerebrovascular diseases may lead to a poor outcome in COVID-19 patients (Pranata et al., 2020). In our meta-analysis, patients with cerebrovascular diseases had a 2.51-fold increased risk to developing severe COVID-19. Among hospitalized COVID-19 patients with cerebrovascular disease the risk of death was 2.82-fold higher when compared to hospitalized COVID-19 patients without cerebrovascular disease. The meta-analysis conducted by Wang et al. (2020) revealed that cerebrovascular disease was associated with a 3.89-fold higher risk of developing severe COVID-19 (Wang et al., 2020d). In relation to the risk of death, Tian et al. (2020) and Pranata et al. (2020) showed that COVID-19 patients with cerebrovascular disease had an increased risk of death (Pranata et al., 2020; Tian et al., 2020b). The pathophysiological mechanism that explains the poor clinical evolution of COVID-19 in patients with cerebrovascular disease has not yet been reported. However, cerebrovascular disease seems to act in conjunction with other comorbidities, such as cardiovascular problems (Pranata et al., 2020).

Current studies have shown that cancer patients infected with SARS-CoV-2 were more likely to have intubation and mortality when compared to patients without cancer (Venkatesulu et al., 2020). Analysing severity and mortality, our metaanalysis showed that cancer patients had approximately a 2-fold increased risk of mortality during hospitalization for COVID-19. However, no association was found between cancer patients and severe COVID-19 in our analysis. Venkatesulu et al. (2020) reported that cancer patients were associated with a 2.58, 2.18, 2.43, 2.54-fold higher risk of severity, ICU admission, intubation and mortality during SARS-Cov-2 infection, respectively. Moreover, the authors found that hematologic cancer was associated with a 2.39-fold increased risk of death from COVID-19, but this association was not found in lung, gastrointestinal and breast cancers (Venkatesulu et al., 2020). Several factors may contribute to elevated complications during the pathogenesis of COVID-19 in cancer patients, such as anticancer therapy, immunocompromised state, and other physiologic alteration, depending on the type of cancer (Gosain et al., 2020; Zhang et al., 2020e). Chemotherapy, for example, affects cells of the immune system causing immunosuppression, favoring COVID-19 morbidity (Bersanelli, 2020).

Previous meta-analyses have evaluated the influence of comorbidities on susceptibility to COVID-19. However, our meta-analysis included a considerable number of studies (48 articles) and patients with COVID-19 (n = 344,290). The limitations of this study were: (1) presence of publication bias in some analysis; (2) detection of heterogeneity among the meta-analysed studies; (3) low sample number in some comorbidities; (4) lack of detailed information on patients' comorbidities in the included studies, and (5) the small sample size in some studies. (TNR font 10 – justified – space 1,5).

5. Conclusion

In conclusion, our meta-analysis showed sufficient evidence that hypertension, diabetes, cardiovascular, chronic pulmonary, chronic kidney and cerebrovascular diseases increase the risk of severity and mortality in COVID-19 patients. In addition, malignancy showed increase the risk of death by COVID-19. Therefore, we suggest that the mentioned comorbidities may be an important predictor of an unfavourable outcome for COVID-19, contributing to the prognosis of severe cases of the disease.

We suggest that future studies may assess the risk and severity of mortality in individuals who have two or more preexisting comorbidities combined. The quantity of pre-existing comorbidity in an individual may be proportional to clinical complications caused by COVID-19. Therefore, it would be important to assess this condition to clarify which specific comorbidities combined can further increase the risk of the disease.

Conflicts of interest

All authors declare that there are no conflicts of interest.

Acknowledgments

The authors grateful to the Universidade Federal de Alagoas – UFAL, Instituto de Ciências Biológicas e da Saúde – ICBS, Programa de Pós-Gradução em Ciências da Saúde – PPGCS, and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES, for having contributed to the elaboration of this article.

References

Abd El-Aziz, T. M., & Stockand, J. D. (2020). Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. In Infection, Genetics and Evolution (Vol. 83, p. 104327). Elsevier. https://doi.org/10.1016/j.meegid.2020.104327

Adapa, S., Chenna, A., Balla, M., Merugu, G. P., Koduri, N. M., Daggubati, S. R., Gayam, V., Naramala, S., & Konala, V. M. (2020). COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation. Journal of Clinical Medicine Research. https://doi.org/10.14740/jocmr4200

Aggarwal, G., Cheruiyot, I., Aggarwal, S., Wong, J., Lippi, G., Lavie, C. J., Henry, B. M., & Sanchis-Gomar, F. (2020). Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. Current Problems in Cardiology, 45(8), 100617. https://doi.org/10.1016/j.cpcardiol.2020.100617

Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., Du, B., Aboodi, M., Wunsch, H., Cecconi, M., Koh, Y., Chertow, D. S., Maitland, K., Alshamsi, F., Belley-Cote, E., & Rhodes, A. (2020). Surviving Sepsis Campaign: Guidelines on the Management of Critically III Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, E440–E469. https://doi.org/10.1097/CCM.00000000004363

Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M. C., O'Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020). Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. In Allergy: European Journal of Allergy and Clinical Immunology (75(7), 1564–1581). Wiley Online Library. https://doi.org/10.1111/all.14364

Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. Journal of the American Society of Nephrology, 23(10), 1631–1634. https://doi.org/10.1681/ASN.2011111078

Bersanelli, M. (2020). Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy, 12(5), 269–273. https://doi.org/10.2217/imt-2020-0067

Charlotte, P., Gaël, G., Huu, T. H. P. P., Marine, B., Guillaume, C., Hatem, K., Véronique, E., Christian, C., Daniel, H., & Govind, S. (2020). Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area - a retrospective cohort study. Swiss Medical Weekly, 50(2930). https://doi.org/10.4414/smw.2020.20314

Chen, F., Fang, Z., M., Liu, Y., Zhang, Y., Zhang, K., Su, D. zhen, Meng, X., & Zhang, Y. (2020d). The characteristics and outcomes of 681 severe cases with COVID-19 in China. Journal of Critical Care, 60, 32–37. https://doi.org/10.1016/j.jcrc.2020.07.003

Chen, T. L., Dai, Z., Mo, P., Li, X., Ma, Z., Song, S., Chen, X., Luo, M., Liang, K., Gao, S., Zhang, Y., Deng, L., & Xiong, Y. (2020b). Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 75(9), 1788–1795. https://doi.org/10.1093/gerona/glaa089

Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., Wang, T., Guo, W., Chen, J., Ding, C., Zhang, X., Huang, J., Han, M., Li, S., Luo, X., & Ning, Q. (2020c). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. The BMJ, 368. https://doi.org/10.1136/bmj.m1091

Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang, B., Ding, J., & Li, F. (2020a). Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically III Patients With Coronavirus Disease 2019. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa449

Daccord, C., Touilloux, B., & Von Garnier, C. (2020). Asthma and COPD management during the COVID-19 pandemic. Revue Medicale Suisse, 16(692), 933–938.

Dang, J. z., Zhu, G. y., Yang, Y. J., & Zheng, F. (2020). Clinical characteristics of coronavirus disease 2019 in patients aged 80 years and older. Journal of Integrative Medicine, 18(5), 395–400. https://doi.org/10.1016/j.joim.2020.07.002

de la Rica, R., Borges, M., Aranda, M., Del Castillo, A., Socias, A., Payeras, A., Rialp, G., Socias, L., Masmiquel, L., & Gonzalez-Freire, M. (2020). Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: A retrospective cohort study. Microorganisms. https://doi.org/10.3390/microorganisms8081106

de Moura, E. L., dos Santos, A. C. M., da Silva, D. M., dos Santos, B. B., Figueredo, D. de S., Moura, A. W. A., da Silva, A. F., Tanabe, I. S. B., de Lira Tanabe, E. L., Lira Neto, A. B., Pereira e Silva, A. C., de Carvalho Fraga, C. A., de Lima Filho, J. L., de Farias, K. F., & Martins de Souza, E. V. (2020). Association of Polymorphisms in Cytokine genes with susceptibility to Precancerous Lesions and Cervical Cancer: A systematic review with meta-analysis. In Immunological Investigations. https://doi.org/10.1080/08820139.2020.1778023

Deng, Y., Liu, W., Liu, K., Fang, Y. Y., Shang, J., Zhou, L., Wang, K., Leng, F., Wei, S., Chen, L., & Liu, H. G. (2020). Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chinese Medical Journal, 133(11), 1261–1267. https://doi.org/10.1097/CM9.00000000000824

Drawz, P. E., Alper, A. B., Anderson, A. H., Brecklin, C. S., Charleston, J., Chen, J., Deo, R., Fischer, M. J., He, J., Hsu, C. Y., Huan, Y., Keane, M. G., Kusek, J. W., Makos, G. K., Miller, E. R., Soliman, E. Z., Steigerwalt, S. P., Taliercio, J. J., Townsend, R. R., ... Ojo, A. (2016). Masked hypertension and elevated nighttime blood pressure in CKD: Prevalence and association with target organ damage. Clinical Journal of the American Society of Nephrology, 11(4), 642–652. https://doi.org/10.2215/CJN.08530815

Fan, C., Li, K., Ding, Y., Lu, W. L., & Wang, J. (2020). ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. MedRxiv. https://doi.org/10.1101/2020.02.12.20022418

Fang, H., Liu, Q., Xi, M., Xiong, D., He, J., Luo, P., & Li, Z. (2020). Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19. Journal of Investigative Medicine. https://doi.org/10.1136/jim-2020-001555

Feng, Y., Ling, Y., Bai, T., Xie, Y., Huang, J., Li, J., Xiong, W., Yang, D., Chen, R., Lu, F., Lu, Y., Liu, X., Chen, Y., Li, X., Li, Y., Summah, H. D., Lin, H., Yan, J., Zhou, M., ... Qu, J. (2020). COVID-19 with Different Severities: A Multicenter Study of Clinical Features. American Journal of Respiratory and Critical Care Medicine, 201(11), 1380–1388. https://doi.org/10.1164/rccm.202002-0445OC

Gosain, R., Abdou, Y., Singh, A., Rana, N., Puzanov, I., & Ernstoff, M. S. (2020). COVID-19 and Cancer: a Comprehensive Review. Current Oncology Reports, 22(5), 53. https://doi.org/10.1007/s11912-020-00934-7

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K. Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., ... Zhong, N. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382(18), 1708–1720. https://doi.org/10.1056/NEJMoa2002032

Guisado-Vasco, P., Valderas-Ortega, S., Carralón-González, M. M., Roda-Santacruz, A., González-Cortijo, L., Sotres-Fernández, G., Martí-Ballesteros, E. M., Luque-Pinilla, J. M., Almagro-Casado, E., La Coma-Lanuza, F. J., Barrena-Puertas, R., Malo-Benages, E. J., Monforte-Gómez, M. J., Diez-Munar, R., Merino-Lanza, E., Comeche-Casanova, L., Remirez-de-Esparza-Otero, M., Correyero-Plaza, M., Recio-Rodríguez, M., & Carnevali-Ruiz, D. (2020). Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective obser. EClinicalMedicine, 100591. https://doi.org/10.1016/j.eclinm.2020.100591

Harwood, R., & Sinha, I. (2020). Diagnosis of COVID-19 in children: The story evolves. In BMC Medicine (Vol. 18, Issue 1, pp. 1–3). BioMed Central. https://doi.org/10.1186/s12916-020-01631-9

He, Fang, Ding, X. F., Cao, M., Gong, H. Y., Fu, X. Z., Luo, J., Liu, K., Tian, Z. Z., Luo, L., Fan, Y. Y., Li, T., Yao, Q. J., Chen, X. J., Duan, X. L., Chen, L., & Jiang, L. (2020b). Comparative Analysis of 95 Patients with Different Severity in the Early Outbreak of COVID-19 in Wuhan, China. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020. https://doi.org/10.1155/2020/4783062

He, Feng, Luo, Q., Lei, M., Fan, L., Shao, X., Huang, G., Zeng, J., Zhao, Z., Qin, S., Yang, Z., Yu, N., Yang, L., & Cao, J. (2020a). Risk factors for severe cases of COVID-19: A retrospective cohort study. Aging, 12(15), 15730. https://doi.org/10.18632/AGING.103803

Higgins, J. P. T., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. https://doi.org/10.1002/sim.1186 Hu, H., Yao, N., & Qiu, Y. (2020). Comparing rapid scoring systems in mortality prediction of critical ill patients with novel coronavirus disease. Academic Emergency Medicine, 27(6), 461–468. https://doi.org/10.1111/acem.13992

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. https://doi.org/10.1016/S0140-6736(20)30183-5

Imig, J. D., & Ryan, M. J. (2013). Immune and inflammatory role in renal disease. Comprehensive Physiology, 3(2), 957–976. https://doi.org/10.1002/cphy.c120028

Jain, V., & Yuan, J. M. (2020). Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and metaanalysis. International Journal of Public Health, 65, 533–546. https://doi.org/10.1007/s00038-020-01390-7

Javanian, M., Bayani, M., Shokri, M., Sadeghi-Haddad-Zavareh, M., Babazadeh, A., Yeganeh, B., Mohseni, S., Mehraeen, R., Sepidarkish, M., Bijani, A., Rostami, A., Shahbazi, M., Tabari, A. M., Shabani, A., Masrour-Roudsari, J., Hasanpour, A. H., Gholinejad, H. E., Ghorbani, H., & Ebrahimpour, S. (2020). Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Romanian Journal of Internal Medicine = Revue Roumaine de Medecine Interne, 58(3), 161–167. https://doi.org/10.2478/rjim-2020-0013

Jiang, Y., He, S., Zhang, C., Wang, X., Chen, X., Jin, Y., He, Z., Cai, M., Lin, Z., Ying, L., Mou, J., Zhao, H., Lin, R., Zhang, S., Wu, X., Chen, H., & Lv, D. (2020). Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China. Annals of Translational Medicine, 8(8), 547. https://doi.org/10.21037/atm.2020.04.20

Jin, A., Yan, B., Hua, W., Feng, D., Xu, B., Liang, L., & Guo, C. (2020). Clinical characteristics of patients diagnosed with COVID-19 in Beijing. Biosafety and Health, 2(2), 104–111. https://doi.org/10.1016/j.bsheal.2020.05.003

Lai, C. C., Liu, Y. H., Wang, C. Y., Wang, Y. H., Hsueh, S. C., Yen, M. Y., Ko, W. C., & Hsueh, P. R. (2020). Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. In Journal of Microbiology, Immunology and Infection (53(3), 404–412). Elsevier. https://doi.org/10.1016/j.jmii.2020.02.012

Lee, P. I., Hu, Y. L., Chen, P. Y., Huang, Y. C., & Hsueh, P. R. (2020). Are children less susceptible to COVID-19? Journal of Microbiology, Immunology and Infection, 53(3), 371–372. https://doi.org/10.1016/j.jmii.2020.02.011

Lee, S. E., & Kim, Y. S. (2020). Clinical and radiological findings of coronavirus disease 2019 pneumonia: 51 Adult patients from a single center in Daegu, South Korea. Journal of the Korean Society of Radiology, 81(3), 591–603. https://doi.org/10.3348/JKSR.2020.81.3.591

Li, G., Zhou, C. liang, Ba, Y. ming, Wang, Y. ming, Song, B., Cheng, X. bin, Dong, Q. fen, Wang, L. lin, & You, S. sha. (2020c). Nutritional risk and therapy for severe and critical COVID-19 patients: A multicenter retrospective observational study. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2020.09.040

Li, L. quan, Huang, T., Wang, Y. qing, Wang, Z. ping, Liang, Y., Huang, T. bi, Zhang, H. yun, Sun, W., & Wang, Y. (2020d). COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. In Journal of Medical Virology (92(6), 577–583). Wiley Online Library. https://doi.org/10.1002/jmv.25757

Li, T., Lu, L., Zhang, W., Tao, Y., Wang, L., Bao, J., Liu, B., & Duan, J. (2020b). Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan, China. Archives of Gerontology and Geriatrics, 91, 104185. https://doi.org/10.1016/j.archger.2020.104185

Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., Zhang, C., Yue, J., Zhang, Z., Renz, H., Liu, X., Xie, J., Xie, M., & Zhao, J. (2020a). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology, 146(1), 110–118. https://doi.org/10.1016/j.jaci.2020.04.006

Li, Xintao, Guan, B., Su, T., Liu, W., Chen, M., Bin Waleed, K., Guan, X., Gary, T., & Zhu, Z. (2020e). Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: A systematic review and meta-analysis. Heart, 106(15), 1117–1118. https://doi.org/10.1136/heartjnl-2020-317062

Li, Z., Wu, M., Yao, J., Guo, J., Liao, X., Song, S., Li, J., Duan, G., Zhou, Y., Wu, X., Zhou, Z., Wang, T., Hu, M., Chen, X., Fu, Y., Lei, C., Dong, H., Xu, C., Hu, Y., & Yan, J. (2020f). Caution on Kidney Dysfunctions of COVID-19 Patients. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3559601

Liao, Y., Feng, Y., Wang, B., Wang, H., Huang, J., Wu, Y., Wu, Z., Chen, X., Yang, C., Fu, X., & Sun, H. (2020). Clinical characteristics and prognostic factors of COVID-19 patients progression to severe: a retrospective, observational study. Aging, 12(19), 18853–18865. https://doi.org/10.18632/aging.103931

Lin, L., Lu, L., Cao, W., & Li, T. (2020b). Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. In Emerging Microbes and Infections (9(1), 727–732). Taylor & Francis. https://doi.org/10.1080/22221751.2020.1746199

Lin, Q., Zhao, S., Gao, D., Lou, Y., Yang, S., Musa, S. S., Wang, M. H., Cai, Y., Wang, W., Yang, L., & He, D. (2020a). A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action. International Journal of Infectious Diseases, 93, 211–216. https://doi.org/10.1016/j.ijid.2020.02.058

Liu, F., Li, L., Xu, M. Da, Wu, J., Luo, D., Zhu, Y. S., Li, B. X., Song, X. Y., & Zhou, X. (2020a). Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology, 127, 104370. https://doi.org/10.1016/j.jcv.2020.104370

Liu, H., Chen, S., Liu, M., Nie, H., & Lu, H. (2020c). Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging and Disease, 11(3), 668. https://doi.org/10.14336/ad.2020.0502

Liu, Z., Jin, C., Wu, C. C., Liang, T., Zhao, H., Wang, Y., Wang, Z., Li, F., Zhou, J., Cai, S., Zeng, L., & Yang, J. (2020b). Association between initial chest CT or clinical features and clinical course in patients with coronavirus disease 2019 Pneumonia. Korean Journal of Radiology, 21(6), 736. https://doi.org/10.3348/kjr.2020.0171

Lv, Z., Cheng, S., Le, J., Huang, J., Feng, L., Zhang, B., & Li, Y. (2020). Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study. Microbes and Infection, 22(4–5), 195–199. https://doi.org/10.1016/j.micinf.2020.05.007

Moccia, F., Gerbino, A., Lionetti, V., Miragoli, M., Munaron, L. M., Pagliaro, P., Pasqua, T., Penna, C., Rocca, C., Samaja, M., & Angelone, T. (2020). COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. GeroScience, 42, 1021–1049. https://doi.org/10.1007/s11357-020-00198-w

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., Altman, D., Antes, G., Atkins, D., Barbour, V., Barrowman, N., Berlin, J. A., Clark, J., Clarke, M., Cook, D., D'Amico, R., Deeks, J. J., Devereaux, P. J., Dickersin, K., Egger, M., Ernst, E., & Tugwell, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. In PLoS Medicine (p. e1000097). https://doi.org/10.1371/journal.pmed.1000097

Moore, H. B., Barrett, C. D., Moore, E. E., Jhunjhunwala, R., McIntyre, R. C., Moore, P. K., Wang, J., Hajizadeh, N., Talmor, D. S., Sauaia, A., & Yaffe, M. B. (2020). Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID-19: Study design of the phase IIa STARS trial. Research and Practice in Thrombosis and Haemostasis, 4(6), 984–996. https://doi.org/10.1002/rth2.12395

Morrison, A. R., Johnson, J. M., Griebe, K. M., Jones, M. C., Stine, J. J., Hencken, L. N., To, L., Bianchini, M. L., Vahia, A. T., Swiderek, J., Ramesh, M. S., Peters, M. A., & Smith, Z. R. (2020). Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Journal of Autoimmunity, 114, 102512. https://doi.org/10.1016/j.jaut.2020.102512

Namendys-Silva, S. A., Alvarado-Ávila, P. E., Domínguez-Cherit, G., Rivero-Sigarroa, E., Sánchez-Hurtado, L. A., Gutiérrez-Villaseñor, A., Romero-González, J. P., Rodríguez-Bautista, H., García-Briones, A., Garnica-Camacho, C. E., Cruz-Ruiz, N. G., González-Herrera, M. O., García-Guillén, F. J., Guerrero-Gutiérrez, M. A., Salmerón-González, J. D., Romero-Gutiérrez, L., Canto-Castro, J. L., & Cervantes, V. H. (2020). Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study. Heart and Lung. https://doi.org/10.1016/j.hrtlng.2020.10.013

Nicodemus, K. K. (2008). Catmap: Case-control and TDT meta-analysis package. BMC Bioinformatics, 9(1), 130. https://doi.org/10.1186/1471-2105-9-130

Parra-Bracamonte, G. M., Lopez-Villalobos, N., & Parra-Bracamonte, F. E. (2020). Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Annals of Epidemiology. https://doi.org/10.1016/j.annepidem.2020.08.005

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. [e-book]. Santa Maria. Ed. UAB/NTE/UFSM. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf.

Pranata, R., Huang, I., Lim, M. A., Wahjoepramono, E. J., & July, J. (2020). Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19–systematic review, meta-analysis, and meta-regression. Journal of Stroke and Cerebrovascular Diseases, 29(8), 104949. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104949

Raj, D. S., Pecoits-Filho, R., & Kimmel, P. L. (2015). Inflammation in Chronic Kidney Disease. In Chronic Renal Disease. https://doi.org/10.1016/B978-0-12-411602-3.00017-2

Rando, H. M., Greene, C. S., & Robson, M. P. (2020). SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics. Manubot. https://greenelab.github.io/covid19-review/

Robson, B. (2020). Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Computers in Biology and Medicine, 119, 103670. https://doi.org/10.1016/j.compbiomed.2020.103670

Santos, C. M. D. C., Pimenta, C. A. D. M., & Nobre, M. R. C. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Rev Latino-Am Enfermagem. https://doi.org/10.1590/S0104-11692007000300023

Shang, Y., Liu, T., Wei, Y., Li, J., Shao, L., Liu, M., Zhang, Y., Zhao, Z., Xu, H., Peng, Z., Zhou, F., & Wang, X. (2020). Scoring systems for predicting mortality for severe patients with COVID-19. EClinicalMedicine, 24, 100426. https://doi.org/10.1016/j.eclinm.2020.100426

Shi, P., Ren, G., Yang, J., Li, Z., Deng, S., Li, M., Wang, S., Xu, X., Chen, F., Li, Y., Li, C., Yang, X., Xie, Z., Wu, Z., & Chen, M. (2020a). Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: A multicentre retrospective study. Epidemiology and Infection, 148. https://doi.org/10.1017/S0950268820002332

Shi, Y., Tan, M., Chen, X., Liu, Y., Huang, J., Ou, J., & Deng, X. (2020b). Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. MedRxiv. https://doi.org/10.1101/2020.03.12.20034736

Shu, L., Wang, X., Li, M., Chen, X., Ji, N., Shi, L., Wu, M., Deng, K., Wei, J., Wang, X., Cao, Y., Yan, J., & Feng, G. (2020). Clinical characteristics of moderate COVID-19 patients aggravation in Wuhan Stadium Cabin Hospital: A 571 cases of retrospective cohort study. Journal of Medical Virology. https://doi.org/10.1002/jmv.26414

Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 25(9), 603–605. https://doi.org/10.1007/s10654-010-9491-z

Taghavi-Farahabadi, M., Mahmoudi, M., Soudi, S., & Hashemi, S. M. (2020). Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes. Medical Hypotheses, 144, 109865. https://doi.org/10.1016/j.mehy.2020.109865

Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 20, 363–374. https://doi.org/10.2217/imt-2020-0067

Tian, H., Liu, Y., Li, Y., Wu, C. H., Chen, B., Kraemer, M. U. G., Li, B., Cai, J., Xu, B., Yang, Q., Wang, B., Yang, P., Cui, Y., Song, Y., Zheng, P., Wang, Q., Bjornstad, O. N., Yang, R., Grenfell, B. T., ... Dye, C. (2020a). An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science, 368(6491), 638–642. https://doi.org/10.1126/science.abb6105

Tian, W., Jiang, W., Yao, J., Nicholson, C. J., Li, R. H., Sigurslid, H. H., Wooster, L., Rotter, J. I., Guo, X., & Malhotra, R. (2020b). Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. Journal of Medical Virology, 92, 1875–1883. https://doi.org/10.1002/jmv.26050

Vena, A., Giacobbe, D. R., Di Biagio, A., Mikulska, M., Taramasso, L., De Maria, A., Ball, L., Brunetti, I., Loconte, M., Patroniti, N. A., Robba, C., Delfino, E., Dentone, C., Magnasco, L., Nicolini, L., Toscanini, F., Bavastro, M., Cerchiaro, M., Barisione, E., & Caglieris, S. (2020). Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clinical Microbiology and Infection, 26(11), 1537–1544. https://doi.org/10.1016/j.cmi.2020.07.049

Venkatesulu, B. P., Chandrasekar, V. T., Girdhar, P., Advani, P., Sharma, A., Elumalai, T., Hsieh, C., Elghazawy, H. I., Verma, V., & Krishnan, S. (2020). A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. MedRxiv: The Preprint Server for Health Sciences. https://doi.org/10.1101/2020.05.27.20115303

Wang, B., Li, R., Lu, Z., & Huang, Y. (2020d). Does comorbidity increase the risk of patients with covid-19: Evidence from meta-analysis. Aging, 12(7), 6049. https://doi.org/10.18632/AGING.103000

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020a). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - Journal of the American Medical Association, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585

Wang, G., Wu, C., Zhang, Q., Wu, F., Yu, B., Lv, J., Li, Y., Li, T., Zhang, S., Wu, C., Wu, G., & Zhong, Y. (2020c). C-reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infectious Diseases, 7(5), ofaa153. https://doi.org/10.1093/ofid/ofaa153

Wang, X., Fang, J., Zhu, Y., Chen, L., Ding, F., Zhou, R., Ge, L., Wang, F., Chen, Q., Zhang, Y., & Zhao, Q. (2020b). Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clinical Microbiology and Infection, 26(8), 1063–1068. https://doi.org/10.1016/j.cmi.2020.03.032 Wang, X., Fang, X., Cai, Z., Wu, X., Gao, X., Min, J., & Wang, F. (2020e). Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. Research, 2020, 2402961. https://doi.org/10.34133/2020/2402961

Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., & Song, Y. (2020a). Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine, 180(7), 934–943. https://doi.org/10.1001/jamainternmed.2020.0994

Wu, J., Zhang, J., Sun, X., Wang, L., Xu, Y., Zhang, Y., Liu, X., & Dong, C. (2020b). Influence of diabetes mellitus on the severity and fatality of SARS-CoV -2 infection. Diabetes, Obesity and Metabolism, 22(10), 1907–1914. https://doi.org/10.1111/dom.14105

Xie, H., Zhao, J., Lian, N., Lin, S., Xie, Q., & Zhuo, H. (2020a). Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver International, 40(6), 1321–1326. https://doi.org/10.1111/liv.14449

Xie, J., Wu, W., Li, S., Hu, Y., Hu, M., Li, J., Yang, Y., Huang, T., Zheng, K., Wang, Y., Kang, H., Huang, Y., Jiang, L., Zhang, W., Zhong, M., Sang, L., Zheng, X., Pan, C., Zheng, R., & Du, B. (2020b). Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Medicine. https://doi.org/10.1007/s00134-020-06211-2

Yang, J. K., Feng, Y., Yuan, M. Y., Yuan, S. Y., Fu, H. J., Wu, B. Y., Sun, G. Z., Yang, G. R., Zhang, X. L., Wang, L., Xu, X., Xu, X. P., & Chan, J. C. N. (2006d). Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Medicine, 23(6), 623–628. https://doi.org/10.1111/j.1464-5491.2006.01861.x

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020a). Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. International Journal of Infectious Diseases, 94, 91–95. https://doi.org/10.1016/j.ijid.2020.03.017

Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020b). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases, 94, 91–95.

Yang, R., Gui, X., Zhang, Y., & Xiong, Y. (2020c). The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients. Expert Review of Respiratory Medicine, 14(8), 835–838. https://doi.org/10.1080/17476348.2020.1761791

Yao, Q., Wang, P., Wang, X., Qie, G., Meng, M., Tong, X., Bai, X., Ding, M., Liu, W., Liu, K., & Chu, Y. (2020). A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. Polish Archives of Internal Medicine, 130(5), 390–399. https://doi.org/10.20452/pamw.15312

Zhang, H., Cao, X., Kong, M., Mao, X., Huang, L., He, P., Pan, S., Li, J., & Lu, Z. (2020c). Clinical and hematological characteristics of 88 patients with COVID-19. International Journal of Laboratory Hematology, 42(6), 780–787. https://doi.org/10.1111/ijlh.13291

Zhang, Jin jin, Dong, X., Cao, Y. yuan, Yuan, Y. dong, Yang, Y. bin, Yan, Y. qin, Akdis, C. A., & Gao, Y. dong. (2020a). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy: European Journal of Allergy and Clinical Immunology, 75(7), 1730–1741. https://doi.org/10.1111/all.14238

Zhang, Jingqi, Wu, J., Sun, X., Xue, H., Shao, J., Cai, W., Jing, Y., Yue, M., & Dong, C. (2020d). Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-Analysis. Epidemiology and Infection, 148(e106), 1–7. https://doi.org/10.1017/S095026882000117X

Zhang, Jun, Yu, M., Tong, S., Liu, L. Y., & Tang, L. V. (2020b). Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. Journal of Clinical Virology, 127, 104392. https://doi.org/10.1016/j.jcv.2020.104392

Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., Jia, P., Guan, H. Q., Peng, L., Chen, Y., Peng, P., Zhang, P., Chu, Q., Shen, Q., Wang, Y., Xu, S. Y., Zhao, J. P., & Zhou, M. (2020e). Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Annals of Oncology, 31(7), 894–901. https://doi.org/10.1016/j.annonc.2020.03.296

Zhao, Q., Meng, M., Kumar, R., Wu, Y., Huang, J., Lian, N., Deng, Y., & Lin, S. (2020). The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis. Journal of Medical Virology, 92(10), 1915–1921. https://doi.org/10.1002/jmv.25889

Zheng, F., Tang, W., Li, H., Huang, Y. X., Xie, Y. L., & Zhou, Z. G. (2020a). Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. European Review for Medical and Pharmacological Sciences, 24(6), 3404–3410. https://doi.org/10.26355/eurrev_202003_20711

Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020b). COVID-19 and the cardiovascular system. Nature Reviews Cardiology, 17(5), 259–260. https://doi.org/10.1038/s41569-020-0360-5

Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., Ye, C., Zhang, P., Xing, Y., Guo, H., & Tang, W. (2020c). Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of Infection, 81(2), e16–e21. https://doi.org/10.1016/j.jinf.2020.04.021

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3

Zhu, Z., Cai, T., Fan, L., Lou, K., Hua, X., Huang, Z., & Gao, G. (2020). Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. International Journal of Infectious Diseases, 95, 332–339. https://doi.org/10.1016/j.ijid.2020.04.041